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   Abstract 
Aberrant function and over-expression of protease-activated receptor 2 (PAR2), a GPCR, is 
associated with various cancers and inflammatory diseases. PAR2-targeting ligands have 
been developed with therapeutic applications but the development of imaging probes is 
lacking. A series of PAR2-targeted fluorescent and 18F-PET imaging agents were synthesized 
and assessed for PAR2-binding. A novel dye-conjugated peptide, Isox-Cha-Chg-ARK(Sulfo-
Cy5)-NH2 (EC50=16nM, KD=38nM), showed >10-fold increase in potency and binding 
affinity for PAR2 compared to the leading known fluorescent probe. A novel PET imaging 
18F-labeled peptide, Isox-Cha-Chg-AR-Dpr([18F]4-FB)-NH2, is the first PAR2-targeted in 
vivo imaging agent. It showed significant uptake in PAR2-expressing prostate cancer cells 
compared to controls (P<0.001) and the 19F-standard was highly potent (EC50=13nM) and 
PAR2-selective. The peptide was 18F-labeled through standard prosthetic group labeling 
(RCY=37±3%, RCP>98%, Am=20±2GBq/µmol, EOS=125±2min, n=4). These probes are 
useful chemical tools that could provide insight into PAR2 expression in vitro and in vivo 
with potential clinical applications in PAR2-related diseases. 
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Chapter 1  
1 Introduction 
1.1 Protease-activated Receptors 
Protease-activated receptors (PARs) are a subfamily of G protein-coupled receptors 
(GPCRs). GPCRs are cell membrane receptors that are involved in a broad range of 
cellular processes, making them common therapeutic targets. They have a characteristic 
seven trans-membrane domain, extracellular ligand-binding site, and intracellular three-
subunit G protein (α, β, and γ). GPCRs cause a cellular response through an intricate 
signal transduction pathway initiated when a ligand binds to, and activates, the receptor. 
Ligand binding initiates a conformational change in the receptor, causing its intracellular 
G protein to replace GDP with GTP.1,2 This replacement allows the α-subunit of the G 
protein to dissociate from the β- and γ-subunits.1,2 The dissociated G protein subunits can 
then elicit various effects on other intracellular signaling proteins or directly on 
functional proteins, such as the adenylate cyclase enzyme or ion channels.1,2 Further, the 
ligand-induced conformational change of the receptor can cause intracellular 
phosphorylation and subsequent recruitment of β-arrestin 1 and 2, which often results in 
receptor internalization, desensitization, and G protein independent signaling.1,2 PAR 
pathways are similar to those of the typical GPCR, except their unique method of ligand 
activation. Typical GPCRs are activated by a free endogenous ligand (Figure 1.1A), 
whereas PARs are activated through a covalently linked tethered ligand.1,2 In an inactive 
state, PARs have N-terminal amino acids that ‘mask’ the ligand. Specific proteases 
cleave off the N-terminal portion of the receptor revealing an ‘unmasked’ tethered ligand 
sequence that binds to the PAR binding region and activates the receptor (Figure 1.1B).1,2 
It has been found that exogenous ligands resembling the tethered ligand sequence can 
activate a PAR in lieu of its endogenous tethered ligand (Figure 1.1C).1,2 
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Figure 1.1: GPCR versus PAR agonist activation comparison. (A) Usual GPCR ligand 
activation, (B) PAR tethered ligand activation, (C) PAR free ligand activation. 
 
1.2 Protease-activated Receptor 2 
There are four known PARs, designated PAR1, PAR2, PAR3, and PAR4. All PARs have 
different but related functions, and have been linked to various diseases; the focus of this 
research is on PAR2. PAR2 is naturally expressed in various tissues, in which the 
pancreas, kidneys, liver, small intestine, and colon show the highest expression.3–5 The 
physiological role of PAR2 is generally involved in inflammation, cell migration, tissue 
metabolism, and gastrointestinal function. However, aberrant function or over-expression 
of PAR2 has been linked to various cancers and inflammatory diseases. More 
specifically, PAR2 is implicated in conditions including arthritis, colitis, asthma, 
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cardiovascular disease, prostate cancer, lung cancer, gastric cancer, colon cancer, 
melanoma, ovarian cancer, and breast cancer.6–21 In cancerous tissue, this undesirable 
activity of PAR2 has been shown to significantly contribute to cancer cell proliferation, 
angiogenesis, and metastasis.8,22,23 Of specific interest, there is up to a 16-fold increase in 
PAR2 expression in colon, lung, breast, prostate, ovarian, and gastric cancers and PAR2 
expression levels have been positively correlated to cancer staging and 
progression.10,13,16,19,20,24,25 PAR2 is therefore an important biological target for 
therapeutics and imaging. Optimization of the PAR2-ligand interaction has been 
thoroughly explored, with some ligands showing therapeutic potential.2 There is however 
a paucity of published research into the development of fluorescent ligands and no 
published research available on the development of in vivo imaging agents for PAR2. 
 
1.3 Molecular Imaging 
Molecular imaging is the visualization, characterization, and measurement of biological 
processes at the molecular and cellular levels in living systems.26 It is a technique that is 
able to non-invasively study cellular processes, diagnose disease, monitor treatment 
response of patients, and stratify diseases of patients. Molecular imaging encompasses 
many imaging modalities such as positron emission tomography (PET), single photon 
emission computed tomography (SPECT), optical, and magnetic resonance (MR) 
imaging. Each of these common molecular imaging modalities have their various 
strengths and weaknesses when it comes to their spatial resolution, sensitivity, and depth 
of penetration (Figure 1.2).27 Optical imaging has strong spatial resolution and sensitivity 
in comparison to the other common molecular imaging modalities, but is limited by its 
depth of penetration in living systems.27 MR, PET, and SPECT imaging are not limited 
by their depth of penetration but have their own shortcomings.27 MR imaging has poor 
sensitivity for its contrast agents whereas nuclear (PET and SPECT) imaging have poor 
resolution compared to the other common molecular imaging modalities.27 Nuclear 
imaging does however have very strong sensitivity compared to the other common 
molecular imaging modalities.27 
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Figure 1.2: Comparison of spatial resolution and molecular sensitivity for various 
imaging modalities. 
A crucial component to molecular imaging involves having a detectable agent referred to 
as a molecular imaging agent. Typical molecular imaging agents contain a targeting 
moiety that binds with high affinity and specificity to the biological target of interest, a 
linker, and an imaging moiety (Figure 1.3). 
 
Figure 1.3: Common imaging agent design. 
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1.4 Fluorescence Imaging 
Fluorescence is the emission of electromagnetic radiation from a substance that has 
absorbed some higher energy electromagnetic radiation, in which visual light emission is 
the most useful for molecular imaging.28 This concept can be utilized for fluorescence 
molecular imaging through the use of fluorescent imaging agents. Similar to other 
imaging agents, these agents typically contain a targeting moiety and a fluorescent 
moiety (similar to Figure 1.3). The most significant limitation for imaging using 
fluorescent imaging agents is that detection through tissue is limited, with a maximum 
penetration of several centimeters.29 They therefore have minimal uses for in vivo 
imaging of animals larger than rats.29 Despite this, fluorescent imaging agents have a 
multitude of important applications, such as investigating biologically relevant 
interactions (i.e. receptor-ligand binding) in in vitro cell studies or small animal models, 
histology staining, and intraoperative imaging for image-guided surgeries (e.g. in tumour 
resection surgery, a fluorescent imaging agent targeting cancer could be used to aid in 
cancer-tissue visualization).29,30 Since PAR2 is linked to various diseases, such as cancer, 
PAR2-specific fluorescent imaging agents have potential applications in all of these 
categories.  
 
1.5 Positron Emission Tomography Imaging 
PET is a powerful, highly sensitive, quantitative, in vivo imaging technique that indirectly 
detects positron (β+) radioactive decay. In PET molecular imaging, a β+ emitting imaging 
agent acts as the source of the signal. These PET imaging agents can be directly labeled 
with a β+ emitter, but for higher molecular weight entities they commonly have a 
targeting moiety linked to an imaging moiety (similar to Figure 1.3), where the imaging 
moiety often makes use of a prosthetic group. The prosthetic group is designed to allow 
for facile labeling with a radioactive isotope and conjugation to the targeting moiety; 
prosthetic group labeling is commonly used since direct labeling of peptide or protein 
targeting moieties is often not synthetically feasible. There are many examples of β+ 
emitting isotopes used for PET, such as fluorine-18, copper-64, carbon-11, nitrogen-13, 
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gallium-68, and oxygen-15.29 Each of these radionuclides have their own advantages and 
limitations; however, the most common radionuclide used today is fluorine-18. Fluorine-
18 has facile cyclotron production, an ideal half-life for radiopharmaceuticals (109.8 
min), diverse chemistry for introduction into various molecules, and the best spatial 
resolution compared to other PET isotopes.31,32 Fluorine-18 is produced from a cyclotron 
through proton irradiation of 18O (a naturally occurring stable isotope of oxygen).29,32 
Although PET requires fluorine-18 (or other β+ emitters), signal detection does not 
directly measure β+ decay. Initially, β+ decay converts a proton into a neutron, a positron 
(an antiparticle counterpart of an electron), and a neutrino (Figure 1.4).32,33 The positron 
will travel until it has lost enough kinetic energy to annihilate with an electron, emitting 
two antiparallel 511 keV gamma photons.29,32 PET imaging uses a scintillator to detect 
these antiparallel gamma photons, in which areas of high radionuclide content result in 
high signal.33 The high energy of these gamma photons ensures they will travel, and be 
detected, through tissue of any applicable distance, unlike other imaging methods such as 
fluorescence imaging.29 Developing PET imaging agents targeting PAR2 can provide 
insight into areas of PAR2 expression in vivo and have potential clinical applications in 
the diagnosis and treatment of various cancers and inflammatory diseases.  
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Figure 1.4: Positron decay, annihilation, and PET detection. 
 
1.6 PAR2 Structure-Activity Relationship History 
As described in section 1.1, PARs are activated through a specific protease that cleaves 
the N-terminus of the receptor to reveal a tethered ligand sequence that binds to and 
subsequently activates the receptor. Initial studies on ligands targeting PAR2 were based 
on the tethered ligand sequence of the native protein. The amino acid sequence of the 
tethered ligand was determined to be SLIGRL and SLIGKV in rodents and humans, 
respectively.34 These sequences and their C-terminal amidated sequences were 
synthesized as six-mer peptides and were found to bind to and activate PAR2.34–37 
Further, it was found that the amidated rodent sequence (SLIGRL-NH2, Figure 1.5A) had 
the highest potency and binding affinity for human PAR2 compared to the other three 
sequences, partially due to the C-terminal amide resembling the secondary amide present 
in the tethered ligand sequence.35–38 Further structure-activity relationship studies 
involved substitution and addition of various natural and unnatural amino acids to 
SLIGRL-NH2. Replacing serine in position one with various heterocyclic residues greatly 
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improved potency and affinity for PAR2, of which 2-furoyl (i.e. 2f-LIGRL-NH2) was the 
best.39 Addition of ornithine to the C-terminus of 2f-LIGRL-NH2 (Figure 1.5B) was 
found to have no noticeable effect on potency or binding affinity, nor did the addition of 
a fluorescent dye to the side chain of ornithine.40,41 Recently, improvements in PAR2 
affinity and potency of 2f-LIGRL-NH2 have been made through the replacement of the 2-
furoyl (2f) group with a 5-isoxazoyl (Isox) group as well as leucine and isoleucine with 
more hydrophobic analogues cyclohexylalanine (Cha) and cyclohexylglycine (Chg).39,42–
44 Originally, the truncated sequence Isox-Cha-Chg-NH2 (Figure 1.5C) showed a ten-fold 
increase in potency compared to 2f-LIGRLO-NH2 through a calcium assay, but later was 
reported to have a reduced affinity for PAR2 through a competitive binding assay.42,43 
This was likely due to the absence of the arginine positive charge; a charge that may 
contribute to a relatively strong ionic interaction with the receptor.43 However, the 
sequence Isox-Cha-Chg-AR-NH2 (Figure 1.5C) showed a greater than ten-fold increase 
in potency and affinity for PAR2 compared to 2f-LIGRL-NH2 in those same assays.43 
 
Figure 1.5: Structure of (A) SLIGRL-NH2, (B) 2f-LIGRLO-NH2, and (C) Isox-Cha-Chg-
X. 
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1.7 Labeling Strategy 
There are several ways to label targeting moieties with fluorine-18; however, due to the 
large number of potentially reactive functional groups, labeling of peptides generally 
proceeds using a prosthetic group. The prosthetic group, N-succinimidyl 4-
[18F]fluorobenzoate ([18F]SFB, Figure 1.6A), was used for labeling of peptides in this 
thesis as it is one of the most common fluorine-18 peptide labeling prosthetic groups, 
which gives quick, efficient, and clean labeling with the ability to be automated.45,46 
Commonly, as completed in this thesis, the 4-fluorobenzoyl (4-FB) with natural fluorine 
(fluorine-19) is conjugated to the targeting moiety to identify the lead candidate(s) 
through biological evaluation before the fluorine-18 version(s) are synthesized using 
[18F]SFB. The Sulfo-Cy5 NHS (Sulfo-Cyanine5 N-hydroxysuccinimide) ester fluorescent 
dye (Figure 1.6B) is a commercially available fluorescent dye that can undergo facile 
conjugation to primary amines, which was also used for labeling of peptides in this thesis. 
 
Figure 1.6: Structure of (A) [18F]SFB and (B) Sulfo-Cy5 NHS ester. 
 
1.8 Computational Distribution Coefficient 
The distribution coefficient (D) is a measure of the hydrophilicity/hydrophobicity of a 
compound. It is a ratio of the concentration of a compound that is dissolved in n-octanol 
compared to its concentration dissolved in water from a mixture of these two immiscible 
solvents at a given pH (Eqn. 1).47  
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D = [ionized	&	unionized	compound	in	octanol][ionized	&	unionized	compound	in	water] 										(1) 
The distribution coefficient is usually expressed as a logarithm of D (logD), in which 
more hydrophobic compounds are generally more soluble in n-octanol thereby having a 
more positive value. More hydrophilic compounds are generally more soluble in water 
thereby having a more negative value. This value can be determined experimentally, or 
by the more feasible route, computationally to give a clogD value.47  
Development of imaging agents and therapeutic drugs can be improved by utilizing 
information from logD or clogD, as there is typically an ideal balance of hydrophobicity 
and hydrophilicity for in vivo applications.47 Molecules with very negative logD or clogD 
values typically have rapid clearance and a difficult time passing biological barriers to get 
to the target in vivo. Molecules with very positive values typically have a high uptake in 
fatty tissue, blood solubility issues, and higher chances of producing toxic metabolites in 
vivo.47  
The clogD values for the compounds developed herein were calculated using Simulations 
Plus MedChem Designer ADMET Predictor.48 This program contains several models 
with over 300 atomic and molecular descriptors as well as various algorithms to select the 
best model and prediction parameters to determine the computed distribution coefficient 
at a desired pH. Generally, the pH is set to 7.4 to resemble physiological conditions. 
 
1.9 Bioluminescence Resonance Energy Transfer β-
Arrestin 2 Recruitment Assay  
Most GPCRs, including PAR2, initiate β-arrestin 2 (arr2) recruitment when a ligand 
binds to its orthosteric site. This signal is often involved in receptor internalization, 
desensitization, and G protein independent signaling.49,50 This recruitment can be used for 
a biological assay to determine receptor-ligand binding. In this assay, cells are transiently 
transfected with genes that encode for PAR2 tagged with enhanced yellow fluorescent 
protein (eYFP) and arr2 tagged with renilla luciferase (rluc). The cell then begins to 
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express both of these proteins, PAR2-eYFP on the cell membrane and arr2-rluc in the 
cytoplasm (Figure 1.7). Cells are then incubated with a PAR2-targeting ligand followed 
by h-coelenterazine. Renilla luciferase is an enzyme that catalyzes h-coelenterazine to 
emit at λmax = 480 nm (i.e. bioluminescence). If arr2-rluc is in close proximity with 
PAR2-eYFP, resonance energy transfer occurs from the emitted wavelength to eYFP, 
which than subsequently re-emits at λmax = 527 nm. Both emissions are recorded and 
expressed as a ratio of eYFP over rluc-h-coelenterazine emission to control for 
transfection efficiency. The larger the ratio value, the more arr2 recruitment that 
occurred. This is completed at various concentrations of ligand of interest in order to 
determine a dose-response curve and subsequent EC50 value as a measure of potency. 
 
Figure 1.7: BRET β-arrestin 2 assay principle.  
Step 1: binding of agonist to PAR2. Step 2: continuous h-coelenterazine-rluc bioluminescence. Step 3: arr2 
recruitment. Step 4: resonance energy transfer. Step 5: emission of eYFP. 
 
1.10 Calcium Assay 
Similar to β-arrestin 2 recruitment, most GPCRs, including PAR2, initiate calcium 
release when activated by a ligand, which can also be used for a biological assay. Usually 
this calcium acts as a secondary messenger for the cell and delivers a cellular response. In 
this assay, a fluorescent dye, Fluo-4, is incubated with PAR2-expressing cells. Fluo-4 
enters the cell, is activated by an enzyme, chelates calcium, and subsequently, emits 
fluorescence following the appropriate excitation (Figure 1.8). To reduce extracellular 
calcium reporting, Fluo-4 is designed to be activated only by intracellular enzymes. The 
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inactive Fluo-4 cannot chelate calcium and can passively diffuse across the cell 
membrane. The activated Fluo-4 can chelate calcium and cannot diffuse across the cell 
membrane, thereby ‘trapping’ it inside the cell and chelating only intracellular calcium. 
To control for variation within the experiment, each measurement is expressed as a 
percentage of maximum fluorescence through the use of ionomycin. Ionomycin is an 
ionophore that substantially increases the permeability of the cell membrane to calcium; 
since the extracellular fluid is supplemented with calcium, the limiting factor in the 
maximum response is the activated Fluo-4. This assay was used to determine PAR2 
selective binding through the use of cells expressing and not expressing PAR2. 
 
Figure 1.8: Calcium assay principle for a PAR2-expressing cell.  
Step 1: passive uptake of Fluo-4 I (inactive) and esterase conversion to Fluo-4 A (active). Step 2: binding 
of agonist to PAR2. Step 3: calcium release due to agonist binding. Step 4: excitation and emission of Fluo-
4 A chelated calcium. 
 
1.11 Purpose of Thesis 
The purpose of this thesis is to develop and evaluate an improved fluorescent and the first 
ever in vivo imaging agents targeting PAR2. The first goal was to synthesize and evaluate 
novel PAR2-targeting peptides with primary amines to allow for facile conjugation of 
imaging components based on known PAR2-selective peptides. The second goal was to 
develop an improved PAR2-selective fluorescent probe through the conjugation of a 
Sulfo-Cy5 NHS ester dye to the lead peptide. The third goal was to develop the first ever 
in vivo imaging agent targeting PAR2 through the radiolabeling of the lead peptide with 
13 
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[18F]SFB for use in PET imaging. To determine the lead candidates for radiolabeling, 
peptide standards with [19F]4-fluorobenozyl were synthesized and evaluated for PAR2-
binding prior to radiolabeling. All peptides were synthesized through standard Fmoc-
solid phase peptide synthesis (SPPS) and screened for their imaging ability by 
determining PAR2 potency using a BRET β-arrestin 2 recruitment assay, PAR2 
selectivity using a calcium signaling assay, and hydrophobicity/hydrophilicity using 
clogD values. Lead imaging agents were then evaluated in vitro in prostate cancer cells 
and will continue to be evaluated ex vivo and in vivo in a preclinical model of prostate 
cancer. 
14 
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Chapter 2  
2 A Potent and High Affinity Fluorescent Probe for 
Protease-Activated Receptor 2 
2.1 Introduction 
Protease-activated receptors (PARs) are a class of G protein-coupled receptors (GPCRs) 
that are self-activated by a tethered ligand after a protease cleaves an N-terminal portion 
of the protein. There are four subtypes, denoted PAR1-PAR4. In PAR2, various proteases 
(e.g. trypsin, tryptase, Granzyme A, KLK4) are known to reveal the tethered ligand 
sequence SLIGKV (humans) and SLIGRL (rodents).1–5 
PAR2 is naturally expressed in various tissues (e.g. pancreas, liver, small intestine, colon) 
and is involved in inflammation and cell migration.6–8 However, abnormal function and 
inappropriate expression of PAR2 has been linked to various cancers and inflammatory 
diseases. More specifically, PAR2 is implicated in conditions such as arthritis, colitis, 
asthma, cardiovascular disease, prostate cancer, lung cancer, gastric cancer, melanoma, 
ovarian cancer, and breast cancer.9–23 In cancerous tissue, this undesirable activity of 
PAR2 has been shown to significantly contribute to cell proliferation, angiogenesis, and 
metastasis.11,24,25  
Exogenous agonists have been developed, which bind and activate PAR2. Initial reports 
synthesized and evaluated peptides that resemble the tethered ligand sequences SLIGKV 
and SLIGRL as well as their amidated analogues, and showed that SLIGRL-NH2 (1, 
Figure 2.1) had the highest potency/affinity for human PAR2, which has thus been widely 
used as a PAR2 agonist with micromolar potency.2,26,27 Extensive structure-activity 
relationship studies have involved substitutions of various natural and unnatural amino 
acids into these sequences, generating peptides with improved potency. In particular, 
substituting the serine residue in the first position with various heterocycles (e.g. 2-
furoyl, 5-isoxazoloyl, 3-pyridoyl, 4-(2-methyloxazoloyl), and 2-aminothiazol-4-oyl) has 
substantially improved potency and affinity for PAR2.28 Of these, 2-furoyl (2f) based 
peptides initially showed the best improvements and have been the most widely used. 
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Addition of ornithine to the C-terminus of the 2f-LIGRL-NH2 hexapeptide (2, Figure 2.1) 
and conjugation of various bulky substituents to the side chain of that ornithine (e.g. 
Alexa Fluor 594, 3 and DTPA(Eu), 4, Figure 2.1) have shown no appreciable effect on 
their potency, affinity, or selectivity for PAR2.29,30 More recently, Isox-Cha-Chg (5-
isoxazoloyl-cyclohexylalanine-cyclohexylglycine) based peptides developed by Yau et al. 
(2016) and Jiang et al. (2017), most notably Isox-Cha-Chg-AR-NH2 (7, Figure 2.1), have 
shown substantial improvements in potency and affinity for PAR2.31,32 
 
Figure 2.1: Known PAR2-targeting peptide agonists.26,29–33 
PAR2-targeting imaging probes developed to date have been limited, with only several 
fluorescent and tritiated probes having been reported.27,29,30,34,35 In particular, 3 has been 
the best fluorescent probe developed thus far with sub-micromolar affinity and with an 
Alexa Fluor 594 fluorescent dye (excitation maximum = 590 nm, emission maximum = 
617 nm).29 Development of higher affinity fluorescent probes improve uptake in cells and 
tissues expressing the receptor, which can result in benefits such as reduced off target 
binding, less compound required, and reduced adverse effects. Development of red-
shifted fluorescent probes allow for improved in vivo imaging in small animals due to 
less absorption and scattering from biomolecules of the red-shifted light compared to 
blue-shifted light. Fluorescent probes targeting this receptor can act as useful chemical 
tools for various in vitro experiments (e.g. competitive binding assays, determination of 
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PAR2 expression levels, insight into PAR2 trafficking), for imaging PAR2 in small 
animals in vivo, and that have potential clinical relevance in PAR2-related diseases such 
as in pathological histology staining or intraoperative imaging for image guided surgery.  
This work describes the development of Isox-Cha-Chg-AR-NH2 related peptides that 
would allow for facile conjugation of imaging components in order to develop an 
improved PAR2-targeting fluorescent probe with low nanomolar affinity/potency for 
PAR2 and with a red-shifted fluorescent dye (Sulfo-Cy5, excitation maximum = 646 nm, 
emission maximum = 662 nm). In addition, this work describes the evaluation of the 
improved fluorescent probe in vitro. The insights gained from compounds like 3 and 4, as 
well as reports demonstrating that the N-terminal portion of PAR2-targeting peptides are 
much more crucial for binding than the C-terminal portion, led us to make modifications 
to the C-terminus of 7 that contain a free primary amine for Sulfo-Cy5 dye 
conjugation.29,30,32 
 
20 
 
20 
2.2 Results and Discussion 
2.2.1 General Peptide Synthesis Strategy 
All peptides (2, 6-12, and 14-15) were synthesized using standard Fmoc-solid phase 
peptide synthesis (SPPS) using a solid support MBHA Rink amide resin or 1,6-
diaminohexane trityl resin (Scheme 2.1). 
 
Scheme 2.1: General procedure for Fmoc-SPPS. 
In addition to standard Fmoc-SPPS, 12 utilized an orthogonal protecting group, 
allyloxycarbonyl (Alloc), followed by subsequent acetylation for its synthesis (Scheme 
2.2).  
 
Scheme 2.2: Alloc deprotection and subsequent acetylation. 
2.2.2 Design, Synthesis, and Evaluation of PAR2-Targeting 
Peptides 
All Peptides were synthesized and evaluated for PAR2-binding through a β-arrestin 2 
recruitment assay in HEK293T cells in an effort to develop a more potent, higher affinity 
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PAR2-selective fluorescent probe. In this assay and cell line reported here, compounds 1, 
2, 6, and 7 showed a similar potency trend to previous reports of binding affinity for 
PAR2 (7 >> 2 >> 6 > 1, from most to least potent, Table 2.1).27,29,32 Following these 
results, the best reported PAR2-targeting peptide (7) from Jiang et al. (2017) was 
modified with a primary amine on the C-terminus in various ways. These modifications 
were made since conjugation of imaging components directly to 7 was not synthetically 
feasible and because the addition of a linker region between the targeting moiety and the 
imaging moiety would help keep bulky substituents (e.g. Sulfo-Cy5) from interfering 
with the receptor-ligand interactions. 
The first approach was the addition of an aminohexyl spacer extending from the peptide 
backbone of 7 to yield 8. This was intended such that conjugation of the dye to the C-
terminus would allow the dye to lie outside of the receptor binding pocket. This 
modification resulted in minimal to no reduction in potency but an increase in 
hydrophobicity from -0.85 to -0.70 (Table 2.1). This hydrophobicity change was 
disconcerting because the addition of the Sulfo-Cy5 dye to the peptides will cause an 
additional substantial increase in hydrophobicity, which is a concern for water solubility 
in its various current and future applications (e.g. in vitro experiments).  
Table 2.1: PAR2-targeted peptides (1-2 and 6-12) with their EC50 and cLogD values.  
# Compound EC50 (nM) pEC50 ± SEM cLogD at pH 7.4 
1 SLIGRL-NH2 7144 5.15 ± 0.03 -1.93 
2 2f-LIGRLO-NH2 210 6.68 ± 0.04 -2.71 
6 Isox-Cha-Chg-NH2 2555 5.59 ± 0.10 2.29 
7 Isox-Cha-Chg-AR-NH2 14 7.86 ± 0.06 -0.85 
8 Isox-Cha-Chg-AR-NH(CH2)6NH2 16 7.79 ± 0.04 -0.70 
9 Isox-Cha-Chg-ARLK-NH2 23 7.65 ± 0.07 -1.29 
10 Isox-Cha-Chg-ARAK-NH2 15 7.82 ± 0.07 -1.77 
11 Isox-Cha-Chg-ARK-NH2 10 8.00 ± 0.09 -1.72 
12 Isox-Cha-Chg-ARK(COCH3)-NH2 16 7.78 ± 0.05 -0.84 
EC50 values determined through a dose-response curve from a β-arrestin 2 recruitment assay in HEK293T 
cells. cLogD values calculated through Simulations Plus MedChem Designer ADMET Predictor.  
In an effort to reduce solubility concerns, 9 was synthesized. The addition of leucine-
lysine (position 6 and 7) to the C-terminus of 7 was synthesized to resemble the 
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previously reported 2, which added ornithine (position 7) to the C-terminus of 2f-LIGRL-
NH2. Although this modification lowered the hydrophobicity, it showed a decrease in 
potency (Table 2.1). From here, alanine-lysine was added to the C-terminus of 7 to 
further decrease hydrophobicity and to reduce steric bulk at position 6 while still 
allowing for the same peptide backbone length as 9 and 2. This yielded 10, which was 
found to have improved potency and hydrophobicity (Table 2.1). Compound 11 was 
synthesized through the direct addition of lysine to the C-terminus of 7. It had a similar 
cLogD as 10 and fortunately showed a slight improvement in potency compared to 7 and 
10 (Table 2.1). Therefore, 11 was taken forward as the lead candidate. 
The lysine side chain of 11 was then acetylated to observe the effect of losing this 
positive charge. This yielded 12, which was found to have only a slight reduction in 
potency compared to 11 (EC50 = 16 nM vs. EC50 = 10 nM, Table 2.1), suggesting this 
charge was not crucial for PAR2 binding, making 11 a good candidate to label with a 
fluorescent dye. 
In addition to potency and hydrophobicity measures, receptor selectively was also 
assessed through an intracellular calcium release assay to ensure the synthesized peptides 
target PAR2 specifically. All known and novel PAR2-targeting peptides (1-2 and 6-12) 
were found to bind selectivity to the PAR2 receptor (Table 2.2, see Appendix 1 for 
PAR2-selectivity traces). This was evaluated by comparing calcium response in 
HEK293T cells expressing PAR2 compared to PAR2 knock out (KO) HEK293T cells. 
As a control, a PAR1-specific agonist (TFLLR-NH2, 13) was assessed for its calcium 
response in both of these cells lines as they both contain the PAR1 receptor (Table 2.2). 
These cells and this control were used (similar to previous reports) because it is known 
that some PAR2-targeting peptides can also bind to PAR1.31,32,36,37  
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Table 2.2: PAR2 selectivity of peptides 1-2 and 6-12. 
# Net % max Ca
2+ release in PAR2 
expressing cells ± SEM 
Net % max Ca2+ release in 
PAR2 KO cells ± SEM 
13 49.3 ± 4.4 67.5 ± 6.6 
1 53.4 ± 7.9 -0.5 ± 0.5 
2 53.0 ± 6.4 0.7 ± 1.2 
6 17.2 ± 4.2 -1.4 ± 1.3 
7 64.6 ± 4.9 -0.5 ± 0.5 
8 68.6 ± 9.3 0.0 ± 0.4 
9 69.9 ± 4.1 -0.4 ± 0.4 
10 67.3 ± 3.9 -1.1 ± 0.5 
11 72.0 ± 5.0 -0.9 ± 0.3 
12 67.3 ± 2.6 -1.4 ± 0.5 
Selectivity measures are shown as calcium response in PAR2 expressing (column two) versus PAR2 KO 
(column three) HEK293T cells. 
2.2.3 Synthesis and Evaluation of PAR2-Targeting Fluorescent 
Probes 
The lead candidate (11) was labeled through the lysine side chain with a Sulfo-Cy5 NHS 
ester fluorescent dye to yield compound 15 (Scheme 2.3). Compound 14 was synthesized 
to resemble the previously reported PAR2-targeting fluorescent probe with the highest 
potency/affinity (3).29 Compound 14 contains an identical PAR2-targeting peptide 
sequence compared to 3, but utilizes Sulfo-Cy5 dye conjugated through the ornithine side 
chain as opposed to an Alexa Fluor 594 dye. The Sulfo-Cy5 dye allows for a more direct 
comparison between the novel Sulfo-Cy5 dye conjugated peptide 15 reported here as well 
as it is a red-shifted and less costly dye. The potency of 14 (EC50 = 296 nM, Table 2.3) 
was similar to its unlabeled counterpart, 2 (EC50 = 210 nM, Table 2.1), which is 
consistent with previous reports of analogous probes modified from this peptide 
sequence.29,38 Compound 15 also showed similar potency (EC50 = 16 nM, Table 2.3) 
compared to its unlabeled counterpart, 11 (EC50 = 10 nM, Table 2.1). More importantly, 
15 was found to have a greater than ten-fold increase in potency compared to 14 (EC50 = 
16 nM vs. EC50 = 296 nM, Table 2.3, Figure 2.2).  
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Scheme 2.3: Synthesis of PAR2-selective fluorescent probe, 15.   
Table 2.3: Evaluation of Sulfo-Cy5 labeled peptides (14 and 15).  
# Compound EC50 (nM) 
pEC50 ± 
SEM 
KD 
(nM) 
pKD ± 
SEM 
cLogD at 
pH 7.4 
14 2f-LIGRLIO(Sulfo-Cy5)-NH2 296 6.53 ± 0.05 430 6.24 ± 0.13 3.57 
15 Isox-Cha-Chg-ARK(Sulfo-Cy5)-NH2 16 7.81 ± 0.09 38 7.20 ± 0.22 3.94 
EC50 values determined through a dose-response curve from a β-arrestin 2 recruitment assay in HEK293T 
cells. KD values determined through a flow cytometry saturation binding experiment. cLogD values 
calculated through Simulations Plus MedChem Designer ADMET Predictor.  
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Figure 2.2: PAR2 β-arrestin 2 recruitment dose-response curves for compound 1, 14, and 
15 in HEK293T cells. 
Similar to the increase in potency, 15 had a similar increase in affinity compared to 14 
(>10 fold) for PAR2 as determined through a saturation binding experiment using flow 
cytometry (KD = 38 nM vs. KD = 430 nM, Table 2.3, and binding curves shown in Figure 
2.3). As a control, competition of 14 and 15 with an excess of a known PAR2-specific 
peptide (7) was completed, which showed a substantial decrease in fluorescence signal 
for both of the fluorescent peptides (see Appendix 2).  
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Figure 2.3: Saturation binding experiments of (A) 14 and (B) 15 in HEK293T cells for 
determination of affinity measures (KD).  
Compound 15 was further evaluated for its in vitro applications using confocal 
microscopy. It was found that this fluorescent probe binds selectively to the receptor and 
does not passively diffuse the cell membrane (Figure 2.4). This is demonstrated by the 
PAR2 expressing PC3 cells showing significant uptake of 15 (Figure 2.4A) compared to 
no uptake in the controls (PAR2 KO PC3 cells, Figure 2.4B, PAR2 expressing PC3 cells 
blocked with excess of an unlabeled known PAR2-selective peptide, 7, Figure 2.4C, and 
PAR2 KO PC3 cells with excess of 7, Figure 2.4D). 
0 250 500 750 1000 1250 1500 1750 2000
0
20
40
60
80
100
[15] (nM)
N
or
m
al
iz
ed
 F
lu
or
es
ce
nc
e
0 250 500 750 1000 1250 1500 1750 2000
0
20
40
60
80
100
[14] (nM)
N
or
m
al
iz
ed
 F
lu
or
es
ce
nc
e
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
27 
 
27 
 
Figure 2.4: Confocal microscopy of 15 in PC3 cells and PAR2 KO PC3 cells.  
Compound 15 (250 nM final concentration) incubated with (A) PC3 cells and (B) PAR2 KO PC3 cells. 
Compound 15 (250 nM final concentration) and PAR2-selective blocking peptide, 7 (2500 nM final 
concentration) co-incubated with (C) PC3 cells and (D) PAR2 KO PC3 cells. Uptake of 15 was effectively 
blocked upon co-incubation with 7. Sulfo-Cy5 signal shown in red and DAPI signal shown in blue. Size 
reference = 20 µm. 
 
2.3 Conclusions 
The novel peptides described here show high potency and selectively for PAR2. The 
various modifications led to slightly different structural and hydrophobic properties and 
each allow for facile conjugation of various imaging components (NHS ester dyes, 
common radioactive prosthetic groups, etc.) while showing minimal to no detrimental 
effect on PAR2 binding. To the best of our knowledge, compound 15 is the most potent, 
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highest affinity PAR2-targeting fluorescent probe reported to date with a red-shifted 
fluorophore and a greater than ten-fold improvement in potency and affinity when 
compared to the best previously reported probe.29 Compound 15 was also validated in an 
in vitro confocal microscopy experiment, further demonstrating its candidacy as a useful 
chemical tool for various in vitro experiments as well as potential clinical relevance in 
PAR2-related diseases.  
 
2.4 Experimental Procedures 
2.4.1 General Methods 
All reagents were purchased from Sigma-Aldrich, ChemImpex, or Thermo Fischer 
Scientific and used without further purification. Peptides were synthesized using standard 
Fmoc-solid phase peptide synthesis (SPPS), cleaved from resin using 95% TFA, 2.5% 
TIPS, and 2.5% H2O for 5 h (except 8: 20% TFA, 2.5% TIPS, 77.5% DCM for 1.5 h), 
precipitated in ice cold tert-butyl methyl ether, lyophilized, purified by preparative RP-
HPLC, and further lyophilized to obtain a dry powder. Purity was assessed by analytical 
RP-HPLC and characterized by HRMS (Table 2.4). The analytical RP-HPLC was 
performed on a system consisting of an analytical Agilent Zorbax SB-C8 column (4.6 x 
150 mm, 5 µm), Waters 600 controller, Waters in-line degasser, and Waters Masslynx 
software (version 4.1). Two mobile phases were used; eluent A (0.1% TFA in 
acetonitrile) and eluent B (0.1% TFA in MilliQ water). The flow rate was set at 1.5 
mLmin-1 over 10 minutes with an additional 5-minute wash (95% solvent A in solvent 
B). A Waters 2998 Photodiode array detector (200-800 nm) and an ESI-MS (Waters 
Quattro Micro API mass spectrometer) were used to monitor the column eluate. The 
preparative RP-HPLC used the same system, eluents, and detection method as mentioned 
above for the analytical RP-HPLC, except that a preparative Agilent Zorbax SB-C8 
column (21.2 x 150 mm, 5 µm) at a flow rate of 20 mLmin-1 was used. The high-
resolution mass spectra for all peptides were determined in positive or negative mode 
using an electrospray ionization (ESI) ion source on a Bruker micrOToF II mass 
spectrometer. Simulations Plus MedChem Designer ADMET Predictor was used to 
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determine the cLogD values at a pH of 7.4.39 All descriptive statistics are reported as 
mean ± SEM where applicable.  
Table 2.4: HRMS data and purity of peptides 2, 6-12, and 14-15. 
Cmpd # Molecular Formula (M) 
Evaluated 
HRMS m/z Calc. m/z Found m/z Purity 
2 C36H63N11O8 [M+H]+ 778.4939 778.4945 > 95 % 
6 C21H32N4O4 [M+Na]+ 427.2321 427.2309 > 95 % 
7 C30H49N9O6 [M+H]+ 632.3884 632.3892 > 95 % 
8 C36H62N10O6 [M+H]+ 731.4932 731.4944 > 95 % 
9 C42H72N12O8 [M+H]+ 873.5674 873.5685 > 95 % 
10 C39H66N12O8 [M+H]+ 831.5205 831.5197 > 95 % 
11 C36H61N11O7 [M+H]+ 760.4834 760.4841 > 95 % 
12 C38H63N11O8 [M+H]+ 802.4939 802.4952 > 95 % 
14 C68H98N13O15S2- M- 1400.6747 1400.6714 > 95 % 
15 C68H96N13O14S2- M- 1382.6641 1382.6589 > 95 % 
Purity assessed by analytical RP-HPLC UV detection. 
2.4.2 Solid-Phase Peptide Synthesis 
All compounds (except 8) were synthesized on Rink amide MBHA resin (256 mg, 0.1 
mmol, 0.39 mmol/g) using standard Fmoc-SPPS procedures and a Biotage® SyrowaveTM 
automated peptide synthesizer (0.4 mmol of HCTU, 0.4 mmol of Fmoc-amino acids, 0.6 
mmol of DIPEA, 1 h coupling). Manual coupling of 5-isoxazoyl (0.3 mmol) was 
performed using HATU (0.3 mmol) and DIPEA (0.6 mmol) for 24 h twice. Compound 8 
was synthesized on 1,6-diaminohexane trityl resin (256 mg, 0.1 mmol, 0.39 mmol/g).  
2.4.3 Solid-Phase Synthesis of 12 
The peptide sequence of 12 was synthesized on resin as described above but with Fmoc-
Lys(Alloc)-OH used in position 6. Subsequently this sequence underwent an Alloc 
deprotection. The resin was swelled in DCM (15 min), washed thrice with dry DCM (3X 
5 mL), and placed under an inert N2 atmosphere. Phenylsilane (296 µL, 2.4 mmol) in dry 
DCM (2 mL) was added to the resin. Tetrakis(triphenylphosphine) palladium(0) (23.1 
mg, 20 µmol) was dissolved in dry DCM (1 mL) and added to the resin. The peptide 
column was flushed with N2 (2 min) before being shaken (5 min). The resin was washed 
thrice with dry DCM (3X 5 mL). The procedure was repeated and shaken (30 min). The 
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resin was washed four times with DCM (4X 5 mL) and DMF (4X 5 mL). Following the 
Alloc deprotection, a solution of 20% acetic anhydride in DMF (5 mL) was added and 
shaken (30 min). The final acetylated on resin peptide was cleaved and purified as usual. 
2.4.4 SPPS Reaction Monitoring 
Two methods were used to monitor SPPS reactions. The first and more frequent method 
is the Kaiser Test. In this method, several resin beads were placed in a test tube followed 
by the addition of 42.5 mM phenol in ethanol (50 µL), 20 µM potassium cyanide in 
pyridine (50 µL), and 280.7 mM ninhydrin in ethanol (50 µL). The mixture was then 
heated (100 °C, 5 min). A positive test indicates the presence of a free amine, which is 
observed by the resin beads turning blue. A negative test indicates no free amine is 
present, which is observed by resin beads remaining the same colour. The second method 
is a small-scale resin cleavage. In this method, several beads and cleavage cocktail (500 
µL) are shaken, worked up, and the desired peptide is confirmed through HPLC-MS. 
2.4.5 Solution-Phase Synthesis of 14 and 15 
Purified 2 or 8 containing a free primary amine (6.16 mg or 6.05 mg, respectively, 6.1 
µmol) were dissolved in DMSO (0.5 mL). DIPEA (12.7 µL, 73 µmol) was then added to 
the reaction followed by the addition of Sulfo-Cy5 NHS ester (5.0 mg, 6.4 µmol) in 
DMSO (0.5 mL). The mixture was shaken at room temperature in the dark (3 h). The 
solution was diluted with a water/acetonitrile mixture, frozen, and lyophilized. The 
product was purified by RP-HPLC, frozen, and lyophilized to yield 14 or 15. 
2.4.6 Cell Lines and Culture Conditions 
All cell culture supplies were purchased from Thermo Fischer Scientific (Waltham, MA, 
US) unless otherwise stated. Human embryonic kidney (HEK-293T, ATCC, Manassas, 
VA, US), CRISPR/Cas9 PAR2 knockout HEK-293T (validated in Mihara et al., 2016), 
prostate cancer (PC3, ATCC, Manassas, VA, US), and CRIPSR/Cas9 PAR2 knockout 
PC3 cells (see Appendix 5 for validation) were cultured in Dulbecco’s Modified Eagle’s 
Medium (HEK293T-derived cell lines) and Ham’s F-12K Nutrient Mixture (PC3-derived 
cell lines) each supplemented with 10% fetal bovine serum (FBS), sodium pyruvate 
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(1mM), and 100 penicillin streptomycin (100 units/mL).40 All culture performed under 
standard conditions (37 °C; 5% CO2). Trypsin (25mM) or PBS-EDTA (1mM) was used 
to passage cell lines. 
2.4.7 BRET β-Arrestin 2 Recruitment Assay 
HEK293T cells were transfected with BRET pair PAR2-eYFP (2 µg) and β-arrestin-2-
rluc (0.2 µg; generous gift from Michel Bouvier) using calcium phosphate and re-plated 
at 24 hours in tissue culture treated white 96-well plates (density approximately 8x102-
1x103 cells/µL). Serial dilutions of agonist (ranging from 300 µM to 300 pM depending 
on the agonist) were prepared in separate 96-well plates in Hank’s Balanced Salt Solution 
(HBSS). Cell media was removed from 96-well plate containing seeded cells. Agonist 
was added from negative control (HBSS) through to highest concentration using a 
multichannel pipette to seeded plates and incubated (37 °C, 10 min). Renilla luciferase 
substrate (h-coelenterazine) was added to each well (5 µM final) and incubated (37 °C, 
10 min). BRET ratios are recorded on Berthold Mithras LB 940. Responses are expressed 
as net emission of eYFP/rluc (calculated by subtracting HBSS baseline eYFP/rluc ratio 
from agonist eYFP/rluc ratio) and normalized to a positive control (1 at 300 µM). 
Experiments were completed in n ≥ 3 and fitted with a non-linear regression analysis 
four-parameter dose-response curve using GraphPad Prism 6 to determine EC50 values. 
2.4.8 Intracellular Calcium Release Assay 
HEK293T or PC3 cells endogenously expressing PAR2 or CRISPR/Cas9 HEK293T or 
PC3 PAR2 KO cells were lifted from confluent T75 flasks using PBS-EDTA (1 mM, 5 
mL). PBS-EDTA was removed by centrifugation. Cells were re-suspended in 500 µL of 
Fluo-4 NW (no wash) dye solution and assay buffer (1 x HBSS, 20 mM HEPES) and 
incubated at ambient temperature on a rocking platform (30 min). Fluo-4 NW cell 
suspensions were then increased to the volume required for the assay with HBSS (with 
Ca2+ and Mg2+). Cells were aliquoted into cuvettes (2 mL/cuvette final volume) 
containing a magnetic stir-bar to keep cells in suspension for the assay. Individual 
cuvettes were loaded into a Photon Technologies Institute (PTI) spectrophotometer. 
Time-based assay parameters were assigned through PTI software as follows: excitation 
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480 nm, emission 530 nm with 8 nm capture window, and 5000 seconds duration. Before 
the addition of agonist, individual cuvette emission was collected for approximately 10 
seconds to obtain baseline emission. Agonist was pipetted into the cuvette (final 
concentration of 10 µM for 2 and 6-12 and 100 µM for 1 and 13) and the fluorescence 
was measured. As a positive control, untreated cuvettes were treated with a calcium 
ionophore (ionomycin calcium salt in DMSO, 3 µM final) to obtain maximum possible 
calcium response. As a negative control, untreated cuvettes were treated with HBSS only 
(no agonist). Response elicited by agonist treatment at individual concentrations (n ≥ 2) 
was expressed as a net percentage of the average maximum response (calculated by 
subtracting no agonist treatment percentage from agonist treatment percentage).  
2.4.9 Flow Cytometry for Determination of KD for 14 and 15 using 
Saturation Binding Experiments 
Assay was performed similar to previous reports.41 HEK293T cells were removed from 
10 cm dish using 5 mL of 1 mM EDTA in PBS. EDTA solution was removed and cell 
pellet was re-suspended in media. Cells were placed into a 25 mL falcon tube, media 
removed, and rinsed with 2% FBS in PBS. The cells were then incubated with a 4% 
paraformaldehyde in PBS solution for 10 min at room temperature followed by being 
rinsed with 2% FBS in PBS. Cells were aliquoted into 300 000 cell portions, PBS was 
removed, and incubated with 500 µL of 2% BSA in HBSS for 15 min at room 
temperature. Cells were then rinsed with 0.1% BSA in HBSS and incubated with 200 µL 
of 14 or 15 at different concentrations (0, 5, 10, 20, 50, 100, 200, 500, 1000, and 2000 
nM) in a 0.1% BSA in HBSS solution for 50 min at room temperature. The cell aliquots 
were washed twice with 1 mL of 2% FBS in PBS, re-suspended in 500 µL of 2% FBS in 
PBS, and fluorescence was measured using a Navios flow cytometer [Beckman Coulter]. 
A 638 nm laser was used for excitation (set at a voltage of 449 V) and detected using a 
660/20 band pass filter. Approximately 5000 cells were gated on forward and side scatter, 
and assessed for Cy5 fluorescence. Experiments were performed in n ≥ 4. The KD values 
for 14 and 15 were calculated using ‘Binding – Saturation, One site – Total’ (Eqn. 2) 
through GraphPad Prism 6.  
Y =	 :;<=∗?@AB? + NS ∗ X + Background (2) 
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where,  
Y represents normalized fluorescence. 
Bmax represents maximum specific binding in the same units as Y. 
X represents the concentration of 14 or 15 in nM. 
KD represents the equilibrium binding constant in the same units as X. The concentration 
of 14 or 15 needed to achieve half-maximum binding at equilibrium. 
NS represents the slope of non-specific binding in Y units divided by X units. 
Background represents the amount of normalized fluorescence with no 14 or 15 added in 
the same units as Y.  
2.4.10 Confocal Microscopy of 15 in PC3 Cells 
PC3 cells were seeded to a density of 75 000 cells/well in a 12-well Nunc plate 
containing coverslips prepared with gelatin (15 minute incubation with a 2% gelatin 
solution followed by 15 minutes of drying). Cell media was removed 24 hours following 
seeding and replaced with serum free Ham’s F-12K media to remove FBS (1 h, 37 °C). 
PC3 cells or PAR2 KO PC3 cells were incubated with 250 nM of dye labeled compound 
(15) with or without 10x concentrated unlabeled compound (7; blocking study) for 30 
minutes at 37 °C. Following incubation, cells were rinsed thrice with PBS (3X 1 mL) to 
remove excess probe and then incubated in a paraformaldehyde solution (1 mL, w/v 4%, 
20 min) to fix cells. Fixed cells were rinsed three additional times with PBS (3X 1 mL) to 
remove excess fixative. Coverslips were mounted to slides using ProLong Gold antifade 
reagent with DAPI (Invitrogen) and cured for 24 hours at 4 °C. Nail polish was used to 
seal slides following curing. Cells were imaged on an Olympus FV1000 confocal system 
at 40x magnification. DAPI was imaged with a diode 405 laser for excitation and 
emission collected at 430-470 nm. Cy5 was imaged with a HeNe2 laser (635 nm) and 
emission recorded at 655-755 nm. Given the large spectral window differences between 
DAPI and Cy5, there were no concerns regarding spectral overlap. Kalman sequential 
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line scanning was employed to further increase confidence in emission profiles of the 
sample.  
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Chapter 3  
3 A Novel PET Probe for In Vivo Imaging of Protease-
Activated Receptor 2 
3.1 Introduction 
Protease-activated receptors (PARs) are a class of G protein-coupled receptors (GPCRs), 
which uniquely are self-activated by a tethered ligand after a specific protease cleaves an 
N-terminal portion of the receptor. Before protease cleavage, the tethered ligand is 
‘masked’ by multiple N-terminal amino acids, but afterwards, the ‘unmasked’ tethered 
ligand is able to bind to and activate the receptor. There are four PAR subtypes, denoted 
PAR1-PAR4. For PAR2, various proteases (e.g. trypsin, tryptase, Granzyme A, KLK4) 
are known to reveal the tethered ligand sequence SLIGKV (humans) and SLIGRL 
(rodents).1–5 
PAR2 is naturally expressed in multiple tissues (e.g. pancreas, liver, small intestine, 
colon) and is involved in inflammation and cell migration.6–8 However, aberrant function 
and over-expression of PAR2 has been linked to various cancers and inflammatory 
diseases. More specifically, PAR2 is implicated in conditions such as arthritis, colitis, 
asthma, cardiovascular disease, prostate cancer, lung cancer, gastric cancer, melanoma, 
ovarian cancer, and breast cancer.9–23 In cancerous tissue, this undesirable activity of 
PAR2 has been shown to significantly contribute to cell proliferation, angiogenesis, and 
metastasis.11,24,25 Of specific interest, there is up to a 16-fold increase in PAR2 expression 
in various cancers and PAR2 expression levels have been positively correlated to cancer 
staging and progression.15,18,21,22,26,27  
Exogenous agonists that resemble the tethered ligand sequences have been developed, 
which bind to and activate PAR2. The tethered ligand sequences SLIGKV and SLIGRL 
as well as their C-terminally amidated analogues were synthesized in initial studies. 
These studies showed that SLIGRL-NH2 (1, Figure 3.1) had the highest potency for 
human PAR2 and is widely used as a PAR2 agonist with micromolar potency.2,28,29 
Extensive structure-activity relationship studies have involved substitutions of various 
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natural and unnatural amino acids into these sequences, which have generated peptides 
with improved potency. In particular, substituting the serine residue in the first position 
with various heterocycles (e.g. 2-furoyl, 5-isoxazoloyl, 3-pyridoyl, 4-(2-
methyloxazoloyl), and 2-aminothiazol-4-oyl) has substantially improved potency and 
affinity for PAR2 to the sub-micromolar range.30 Of these, 2-furoyl (2f) based peptides 
(e.g. 2, Figure 3.1, referred to hereon in as Class I peptides) initially showed the best 
improvements and have been the most widely used. Addition of ornithine to the C-
terminus of the 2f-LIGRL-NH2 hexapeptide (2, Figure 3.1) and conjugation of various 
bulky substituents to the side chain of that ornithine (e.g. Alexa Fluor 594, 3 and 
DTPA(Eu), 4, Figure 3.1) did not appreciably change the potency, affinity, or selectivity 
for PAR2.31,32 More recently, Isox-Cha-Chg (5-isoxazoloyl-cyclohexylalanine-
cyclohexylglycine) based peptides developed by Jiang et al. (2017) and Yau et al. (2016), 
most notably Isox-Cha-Chg-AR-NH2 (7, Figure 3.1), have shown substantial 
improvements in potency and affinity for PAR2.33,34 These Isox-Cha-Chg based peptides 
are referred to hereon in as Class II peptides. In addition, our recent work has shown that 
the addition of primary amines to various positions of 7 (8-11, Figure 3.1) and addition of 
a bulky substituent (15, Figure 3.1) resulted in peptides that maintained PAR2-selectivity 
and potency/affinity for PAR2 in the low nanomolar range (Chapter 2).  
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Figure 3.1: Known PAR2-targeting peptide agonists. (A) SLIGRL-NH2, (B) Class I 
peptides, and (C) Class II peptides.28,31–35 
To our knowledge, PAR2-targeting imaging probes developed to date have been limited 
to in vitro or small animal ex vivo applications, which is because the probes are 
fluorescent or tritiated probes.29,31,32,36,37 A PAR2-targeting in vivo imaging agent could 
provide insight into PAR2 expression in real-time in living systems. In addition, it could 
have potential clinical relevance in the treatment and diagnosis of PAR2-related diseases 
such as various cancers and inflammatory diseases.  
Positron emission tomography (PET) is a highly sensitive, quantitative imaging technique 
that could be used to achieve in vivo imaging of PAR2. Within PET imaging, various 
radionuclides and strategies can be used to label a targeting moiety with a radioactive 
isotope. Fluorine-18 was chosen for this application due to its facile cyclotron production, 
ideal half-life for radiopharmaceuticals (109.8 min), diverse chemistry for introduction 
into various molecules, and the highest spatial resolution compared to other PET 
isotopes.38,39 The N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) prosthetic group was 
used for 18F-labeling as it is one of the most common prosthetic groups for 18F-labeling of 
peptides, because it gives quick, efficient, and clean labeling with the ability to be 
automated.40,41  
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This work describes the design, synthesis, and evaluation of Class I and Class II PAR2-
targeting peptides derived with a 4-fluorobenzoyl group through a free primary amine on 
the peptide. These 4-fluorobenzoyl conjugated peptides act as the 19F-standard of a 
potential 18F-labeled probe for use in in vivo imaging. Further, this work describes the 
radiosynthesis of the radiolabeled lead PAR2-targeting peptide and its evaluation in vitro 
in prostate cancer (PC3) cells. 
 
3.2 Results and Discussion 
3.2.1 Peptide Synthesis 
Similar to Chapter 2, all peptides (2, 6-7, 16-29, and 35) were synthesized using standard 
Fmoc-SPPS using a solid support MBHA Rink amide resin or 1,6-diaminohexane trityl 
resin (Scheme 2.1 – sec. 2.2.1). Compounds 18-19, 22-24, and 26-29 required additional 
orthogonal protecting group allyloxycarbonyl (Alloc) deprotection and subsequent 
conjugation of 4-fluorobenzoic acid (Scheme 3.1A). Compounds 21 and 25 were 
conjugated with the 4-fluorobenozyl group off resin, as the primary amine being 
conjugated was protected by the solid support on resin (Scheme 3.1B and 3.1C, 
respectively). 
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Scheme 3.1: Conjugation of 4-FB to peptides. 
(A) Solid-phase conjugation of 4-fluorobenzoic acid (18-19, 22-24, and 26-29), (B) solution-phase 
conjugation of 4-fluorobenzyl chloride (21), and (C) solution-phase conjugation of 4-fluorobenzoic acid 
(25). 
3.2.2 Synthesis and Evaluation of Class I PAR2-Targeted 
Peptides 
Similar to our previous work in Chapter 2, 2 shows a greater than ten-fold increase in 
potency for PAR2 (187 nM, Table 3.1) compared to 1 (7024 nM, Table 3.1) as 
determined by a β-arrestin 2 recruitment assay in HEK293T cells. This encouraged us to 
investigate Class I peptides for the development of PAR2-targeting PET imaging agents. 
Modifications to Class I peptide sequences were completed to improve PAR2 potency 
first before the conjugation of the 4-fluorobenzoyl group. Previous reports showed that 
the substitution of leucine with alanine at position six of 2f-LIGRL-NH2 improved 
potency.34 Thus, this substitution of 2 was completed to yield 17 where an expected 
increase in potency was observed (99 nM, Table 3.1). In addition, prior reports described 
that the addition of isoleucine to the C-terminus of related peptides (position seven) 
increased potency.30,34 Thus, 18 was synthesized with isoleucine at position seven and 
ornithine at position eight. Compound 18 was also found to have the expected increase in 
potency (56 nM, Table 3.1).  
Next was the conjugation of the 4-fluorobenzoyl group to Class I peptides. The widely 
used PAR2-targeting peptide, 2, and its more potent counterpart, 18, were conjugated to 
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4-fluorobenzoic acid through the primary amine of the ornithine side chain to yield 19 
and 20, respectively. As shown in Table 3.1, 19 showed similar potency (151 nM) 
compared to 2 (187 nM), but with the addition of the isoleucine, 20 showed a substantial 
and unexpected decrease in potency (252 nM) compared to 18 (56 nM). As expected, the 
addition of the 4-fluorobenozyl moiety to these peptides resulted in a noticeable increase 
in hydrophobicity as demonstrated through the cLogD values (Table 3.1).  
Further, PAR2 selectivity was evaluated by measuring intracellular calcium response 
caused by the receptor-peptide interaction in HEK293T cells endogenously expressing 
PAR2 compared to PAR2 knock out (KO) cells. As a control, a PAR1-specific agonist 
(TFLLR-NH2, 13) was assessed for its calcium response in both of these cells lines as 
they both contain the PAR1 receptor (Table 3.1, see Appendix 6 for representative 
examples of traces). These cells and this control were used (similar to previous reports) 
because it is known that some PAR2-targeting peptides can also bind to PAR1.33,34,42,43 
Based on the calcium response in these cells, peptides 17-20 were found to be 
consistently selective to PAR2 (Table 3.1).  
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Table 3.1: Class I PAR2-targeted peptides (2 and 17-20) and control peptides (1 and 13) with their EC50 values, PAR2 selectivity 
measures, and cLogD values.  
# Compound EC50 (nM) 
pEC50 ± 
SEM 
Net % max Ca
2+
 release 
in PAR2 expressing 
cells ± SEM 
Net % max Ca
2+
 
release in PAR2 KO 
cells ± SEM 
cLogD 
at pH 
7.4 
13 TFLLR-NH2 - - 45.6 ± 2.9 63.5 ± 5.5 -0.67 
1 SLIGRL-NH2 7024 5.15 ± 0.03 55.9 ± 4.4 -0.2 ± 0.4 -1.93 
2 2f-LIGRLO-NH2 187 6.73 ± 0.05 58.2 ± 3.2 0.5 ± 0.2 -2.71 
17 2f-LIGRAO-NH2 99 7.00 ± 0.05 54.2 ± 2.9 -0.9 ± 0.2 -3.22 
18 2f-LIGRLIO-NH2 56 7.25 ± 0.07 62.9 ± 6.0 -0.5 ± 0.5 -2.29 
19 2f-LIGRLO(4-FB)-NH2 151 6.82 ± 0.08 57.5 ± 3.5 0.1 ± 1.0 -0.94 
20 2f-LIGRLIO(4-FB)-NH2 252 6.60 ± 0.08 18.5 ± 6.5 -2.2 ± 0.5 -0.51 
EC50 values determined through a dose-response curve from a β-arrestin 2 recruitment assay in HEK293T cells. Selectivity measures are shown as calcium 
response in PAR2 expressing (column five) versus PAR2 KO (column six) HEK293T cells. cLogD values calculated through Simulations Plus MedChem 
Designer ADMET Predictor.  
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3.2.3 Synthesis and Evaluation of First Generation Class II PAR2-
Targeted Peptides 
Since multiple reports have shown that Class II peptides can have improved potency and 
affinity for PAR2 compared to Class I peptides, they were also investigated for the 
development of PAR2-targeting PET imaging agents. The first generation Class II 
peptides were developed from the base peptide sequence of Isox-Cha-Chg. Reports of 
this peptide class including 6 and 16 showed a ten-fold increase in potency for PAR2 
compared to 2 through a calcium assay, but later they were reported to have a reduced 
affinity for PAR2 through a competitive binding assay, likely due to the absence of 
strong hydrogen bond(s) or electrostatic interactions from the loss of the positively 
charged arginine residue when compared to 2.33,34 The results from the β-arrestin 2 
recruitment assay in the HEK293T cell line reported here show a decrease in potency for 
6 and 16 compared to 2; a similar trend to the affinity measures (Table 3.2). Nonetheless, 
the addition of an aminohexyl spacer conjugated to 4-fluorobenzoic acid extending from 
the peptide backbone of 6 was synthesized to yield 21. Unfortunately, peptide 21 showed 
a large reduction in potency (>3000 nM), a loss of PAR2 selectivity, and a large, 
undesirable increase in hydrophobicity (Table 3.2).  
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Table 3.2: First generation Class II PAR2-targeted peptides (6, 16, and 21) with their EC50 values, PAR2 selectivity measures, and 
cLogD values.  
# Compound EC50 (nM) 
pEC50 ± 
SEM 
Net % max Ca
2+
 release 
in PAR2 expressing 
cells ± SEM 
Net % max Ca
2+
 
release in PAR2 KO 
cells ± SEM 
cLogD 
at pH 
7.4 
6 Isox-Cha-Chg-NH2 1925 5.72 ± 0.07 14.6 ± 3.3 -0.1 ± 0.3 2.29 
16 Isox-Cha-Chg-G-NH2 1179 5.93 ± 0.07 22.0 ± 5.5 -2.2 ± 0.1 1.54 
21 Isox-Cha-Chg-NH(CH2)6NH-4-FB >3000 >5.53 7.0 ± 1.9 9.1 ± 4.0 5.00 
EC50 values determined through a dose-response curve from a β-arrestin 2 recruitment assay in HEK293T cells. Selectivity measures are shown as calcium 
response in PAR2 expressing (column five) versus PAR2 KO (column six) HEK293T cells. cLogD values calculated through Simulations Plus MedChem 
Designer ADMET Predictor.  
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3.2.4 Synthesis and Evaluation of Second Generation Class II 
PAR2-Targeted Peptides 
Unsuccessful results from the first generation Class II peptides led to the development of 
a second generation of Class II imaging agents. These were based on known high 
potency/affinity PAR2-selective peptides with the base peptide sequence of Isox-Cha-
Chg-Ala-Arg, such as 7 (Table 3.3, see Appendix 6 for representative examples of PAR2-
selectivity traces) reported by Jiang et al. (2017) and 8-11 (Table 3.3) reported in our 
recent work with the development of PAR2-targeting fluorescent peptides (Chapter 2).34 
This generation of peptides contain the arginine positive charge at position five, which is 
likely the reason they have high affinity and potency in all reported assays compared to 
the first generation Class II peptides.  
Peptides 8-11 from our previous work are highly potent and PAR2-selective peptides that 
contain a free primary amine. Thus, these peptides were used to conjugate a 4-
fluorobenzoyl group to them to yield 22-25. Peptides 22-24 showed similar potencies (10 
to 23 nM, Table 3.3) compared to their unconjugated counterparts 8-11 (13 to 23 nM, 
Table 3.3), making 22 and 24 the most potent 4-fluorbenzoyl conjugated peptides and the 
leading candidates. However, 22-24 showed a lack of PAR2 selectivity, as indicated by 
their calcium response in HEK293T PAR2 KO cells (Table 3.3, see Appendix 6 for 
representative examples of PAR2-selectivity traces). Peptide 25 retained PAR2-
selectivity, but, unfortunately, showed a substantial loss in potency (42 nM) compared to 
its unconjugated counterpart (8) and to 22 and 24 (Table 3.3).  
In our previous work, Isox-Cha-Chg-ARK(COCH3)-NH2 (12) was found to be highly 
potent and have selective binding to PAR2 (Table 2.1, Chapter 2). This suggested that the 
presence of the 4-fluorobenzoyl group caused the lack of selectivity for PAR2 (likely due 
to hydrophobic or pi stacking interactions) as opposed to the loss of charge from the 
amide bond formed on the lysine side chain for peptides 22-24. Therefore, this gave rise 
to the development of a third generation of Class II imaging agents which have the base 
peptide sequence of Isox-Cha-Chg-Ala-Arg-Xaa where the distance of the 4-
fluorobenzoyl group to the peptide backbone of the position six amino acid was modified 
in an effort to improve PAR2 selectivity. 
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Table 3.3: Second generation Class II PAR2-targeted peptides (7-11 and 22-25) with their EC50 values, PAR2 selectivity measures, 
and cLogD values.  
# Compound EC50 (nM) 
pEC50 ± 
SEM 
Net % max Ca
2+
 release 
in PAR2 expressing 
cells ± SEM 
Net % max Ca
2+
 
release in PAR2 KO 
cells ± SEM 
cLogD 
at pH 
7.4 
7 Isox-Cha-Chg-AR-NH2 12 7.92 ± 0.05a 68.8 ± 3.9 -0.5 ± 0.3 -0.85 
11 Isox-Cha-Chg-ARK-NH2 10a 8.00 ± 0.09a 72.0 ± 5.0a -0.9 ± 0.3a -1.72a 
22 Isox-Cha-Chg-ARK(4-FB)-NH2 13 7.89 ± 0.08 63.5 ± 4.6 8.8 ± 2.4 -0.06 
9 Isox-Cha-Chg-ARLK-NH2 23a 7.65 ± 0.07a 69.9 ± 4.1a -0.4 ± 0.4a -1.29a 
23 Isox-Cha-Chg-ARLK(4-FB)-NH2 24 7.61 ± 0.15 70.5 ± 4.7 16.9 ± 4.1 0.26 
10 Isox-Cha-Chg-ARAK-NH2 15a 7.82 ± 0.07a 67.3 ± 3.9a -1.1 ± 0.5a -1.77a 
24 Isox-Cha-Chg-ARAK(4-FB)-NH2 10 8.00 ± 0.06 66.4 ± 6.7 5.8 ± 1.3 -0.13 
8 Isox-Cha-Chg-AR-NH(CH2)6NH2 16a 7.79 ± 0.04a 68.6 ± 9.3a 0.0 ± 0.4a -0.70a 
25 Isox-Cha-Chg-AR-NH(CH2)6NH-4-FB 42 7.37 ± 0.05 58.3 ± 4.4 -1.0 ± 1.0 0.90 
EC50 values determined through a dose-response curve from a β-arrestin 2 recruitment assay in HEK293T cells. Selectivity measures are shown as calcium 
response in PAR2 expressing (column five) versus PAR2 KO (column six) HEK293T cells. cLogD values calculated through Simulations Plus MedChem 
Designer ADMET Predictor. aPeptide data originally found in Chapter 2, Table 2.1 and Table 2.2. 
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3.2.5 Synthesis and Evaluation of Third Generation Class II PAR2-
Targeted Peptides 
The first approach for the third generation Class II imaging agents was to extend the 
linker region that connected the peptide to the 4-fluorobenzoyl group. This was achieved 
by adding a spacer to the lysine side chain of 11, followed by the conjugation of a 4-
fluorobenzoyl group. Two spacers were used for this purpose, 6-aminohexanoyl (Ahx) 
and the longer, more hydrophilic spacer [2-(2-amino)ethoxy)ethoxy]acetyl (AEEA). This 
yielded 26 and 27, respectively, which were selective for PAR2 (Table 3.4) but showed a 
slight reduction in potency (21 nM and 24 nM, respectively, Table 3.4) compared to 22 
(13 nM, Table 3.3).  
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Table 3.4: Third generation Class II PAR2-targeted peptides (26-29) with their EC50 values, PAR2 selectivity measures, and cLogD 
values.  
# Compound EC50 (nM) pEC50 ± SEM 
Net % max Ca
2+
 
release in PAR2 
expressing cells ± 
SEM 
Net % max Ca
2+
 
release in PAR2 KO 
cells ± SEM 
cLogD 
at pH 
7.4 
26 Isox-Cha-Chg-ARK(Ahx-4-FB)-NH2 21 7.68 ± 0.09 52.8 ± 5.5 -0.9 ± 0.2 0.43 
27 Isox-Cha-Chg-ARK(AEEA-4-FB)-NH2 24 7.62 ± 0.06 58.8 ± 6.9 -1.6 ± 0.5 -0.07 
28 Isox-Cha-Chg-ARO(4-FB)-NH2 8 8.13 ± 0.07 55.8 ± 3.8 7.4 ± 1.0 -0.26 
29 Isox-Cha-Chg-AR-Dpr(4-FB)-NH2 13 7.89 ± 0.06 51.0 ± 7.8 -2.1 ± 0.4 -0.71 
EC50 values determined through a dose-response curve from a β-arrestin 2 recruitment assay in HEK293T cells. Selectivity measures are shown as calcium 
response in PAR2 expressing (column five) versus PAR2 KO (column six) HEK293T cells. cLogD values calculated through Simulations Plus MedChem 
Designer ADMET Predictor.  
51 
 
51 
The other approach was to decrease the distance between the peptide backbone and the 4-
fluorobenzoyl group by decreasing the side chain length of the position six lysine on 11. 
Ornithine (O) was first used for this purpose, having one less carbon in its side chain 
compared to lysine, and although this peptide (28) showed good potency (8 nM, Table 
3.4), it was unfortunately non-selective for PAR2 as indicated by its calcium response in 
HEK293T PAR2 KO cells (Table 3.4). Second, 2,3-diaminopropionic acid (Dpr), which 
has three carbons less than the side chain of lysine, was used to further shorten the chain, 
giving 29. Compound 29 showed high potency (13 nM, Table 3.4) compared to 1 and 2 
and similar potency compared to 7 (Figure 3.2) and was PAR2-selective (Table 3.4, see 
Appendix 6 for representative examples of PAR2-selectivity traces), making it the lead 
candidate for 18F-labeling and subsequent in vitro and in vivo experiments.  
 
Figure 3.2: PAR2 β-arrestin 2 recruitment dose-response curves for 1, 2, 7, and 29 in 
HEK293T cells.  
Results from peptides 26, 27, and 29 further supported the insignificance of an amino 
functional group being present at position six of Class II peptides. Further, these results 
support that the specific location of an aromatic group to these Class II peptides is 
important, as the addition of the 4-fluorobenzoyl group can cause non-selective PAR2 
binding as indicated through calcium response in HEK293T PAR2 KO cells, possibly 
caused by hydrophobic or pi stacking interactions between the ligand and a receptor. 
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3.2.6 Radiosynthesis of [18F]29 
The overall synthesis of [18F]29 is outlined in Scheme 3.2. The radiosynthesis of [18F]29 
made use of known radiochemistry.44,45 The first two steps in the synthesis involved 
preparation of the prosthetic group precursor, 32. Briefly, the carboxylic acid of 30 was 
protected with a tert-butyl group, followed by methylation of the tertiary amine using 
MeOTf to obtain the radiolabeling precursor 32. 
 
Scheme 3.2: Synthesis of [18F]29. 
Radiolabeling of 32 with [18F]F- was accomplished through an automated synthetic 
protocol previously developed in our lab to yield the 18F-prosthetic group, 34 (see  
Appendix 7 for the automated synthesis display). Compound 32 was reacted with 
azeotropically dried [18F]F- to obtain tert-butyl [18F]4-fluorobenzoate through a 
nucleophilic aromatic substitution reaction, followed by subsequent deprotection of the 
tert-butyl ester with 5M HCl to yield [18F]33. This product was purified by solid-phase 
extraction, reacted with EDC hydrochloride and NHS to provide the activated ester 
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([18F]34), and purified on RP-HPLC (RCY = 31 ± 3%, RCP > 98%, n = 4, Figure 3.3A, 
see Appendix 8A for 34 and [18F]34 RP-HPLC co-injection).  
The final step in the radiosynthesis was the conjugation of the 18F-prosthetic group to the 
peptide to yield [18F]29. Compound [18F]34 was conjugated to 35 through nucleophilic 
acyl substitution followed by RP-HPLC purification to obtain [18F]29. Peptide 35 did not 
require protecting groups and subsequent deprotection step(s), unlike other peptide 
labeling reports, because the [18F]SFB prosthetic group is preferentially selective for 
primary amines under these conditions and because 35 was designed to contain one 
primary amine. A water and acetonitrile (v/v 1:3) mixture was initially used for this 
conjugation as 35 had poor solubility in pure acetonitrile; however, hydrolysis of [18F]34 
was observed and poor yields of [18F]29 were obtained (RCY = 18 ± 4%, n = 2). 
Acetonitrile was used to prevent hydrolysis despite poor solubility of the starting 
material. Reaction temperatures of 85 °C improved solubility, resulting in improved 
radiochemical yields (RCY = 37 ± 3%, RCP > 98%, Am = 20 ± 2 GBq/µmol, EOS = 125 
± 2 min, n = 4, Figure 3.3B, see Appendix 8B for 29 and [18F]29 RP-HPLC co-injection). 
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Figure 3.3: Overlay of RP-HPLC chromatogram and radio-trace of (A) SFB and 
[18F]SFB, respectively, and (B) 29 and [18F]29, respectively. 
3.2.7 Cell Uptake of [18F]29 in PC3 Cells 
Upon successful synthesis of [18F]29, cell uptake studies were completed in a prostate 
cancer cell line (PC3) that endogenously over-expresses PAR2 as well as in a PAR2 KO 
PC3 cell line. As shown in Figure 3.4, [18F]29 showed a significant uptake in the PAR2 
expressing cell line at 20 and 60 minutes (7.9 ± 0.7%, 7.4 ± 0.7%, respectively) 
compared to the PAR2 KO cell line (2.3 ± 0.1%, 2.3 ± 0.1%, respectively) and the PAR2 
expressing cell line blocked with 7 (1.6 ± 0.2%, 2.1 ± 0.1%, respectively). This suggests 
that there is receptor selective binding as well as that [18F]29 is not passively diffusing 
the cell membrane. This is consistent with our results of a similar, but even more 
hydrophobic fluorescent probe (15), which showed PAR2-selective uptake and no 
passive diffusion across the cell membrane (Figure 2.4, Chapter 2). 
0 2 4 6 8 10
0.0
0.5
1.0
1.5
2.0
0
500
1000
1500
2000
Time (min)
U
V 
A
bs
or
ba
nc
e 
(A
U
)
SFB
[18F]SFB
R
adioactivity (m
V)
0 2 4 6 8 10
0.0
0.1
0.2
0.3
0
200
400
600
800
Time (min)
U
V 
A
bs
or
ba
nc
e 
(A
U
)
29
[18F]29
R
adioactivity (m
V)
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
55 
 
55 
 
Figure 3.4: Cell uptake of [18F]29 in PAR2 KO PC3 cells (white), PC3 cells blocked 
with 20 µM of 7 (grey), and PC3 cells (black).  
A two way ANOVA (cell condition, time) for percent uptake followed by a post-hoc Tukey multiple 
comparisons test was used to assess significance (significance set at 0.05). Overall cell condition effect was 
significant (P < 0.001) but the overall time effect was not significant (P = 0.956). Different letters represent 
significance (P ≤ 0.05). 
 
3.3 Conclusions and Future Work 
3.3.1 Conclusions 
Many novel peptides described here show high potency and selectivity for PAR2, while 
also having potential to be PET imaging agents for PAR2. The first approach to obtain 
these peptides was through the synthesis and evaluation of various Class I peptides (2f-
LIGRLO-NH2 based sequences) for PAR2-binding. These results lead to peptide 18 
being the most potent (EC50 = 56 nM, Table 3.1); however, conjugation of it with a 4-
fluorobenozyl group showed an unexpected decrease in potency, making 19 the leading 
PAR2-targeting Class I imaging agent (EC50 = 151 nM, Table 3.1). The next approach 
was the synthesis and evaluation of Class II peptides (based on Isox-Cha-Chg based 
sequences). The first generation of Class II peptides showed poor potency for PAR2 
(Table 3.2), likely because of the absence of arginine at position five. The second 
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generation of Class II peptides (containing arginine in position five) showed substantial 
improvements in potency (EC50 = 10 to 42 nM, Table 3.3), but the lead candidates 22-24 
showed non-selective PAR2 binding as measured through a calcium assay in HEK293T 
PAR2 KO cells (Table 3.3). The third generation of Class II peptides modified the 
distance of the 4-fluorobenzoyl group to the peptide backbone of the position six amino 
acid since the specific position of this 4-fluorobenzoyl group was the expected cause of 
non-selective PAR2 binding. This generation of Class II peptides had several candidates 
(26, 27, and 29) that showed high potency (EC50 = 13 to 24 nM, Table 3.4) and 
selectivity for PAR2 (Table 3.4).  
The investigation of these various PAR2-targeting probes gave rise to five peptides (19, 
25-27, and 29) that have various structural and hydrophobic properties with strong 
potential as PET imaging agents for PAR2, of which, 29 was the lead candidate (EC50 = 
13 nM, Table 3.4). The 18F-labeled version of 29 was then successfully synthesized with 
radiochemical yields of 37 ± 3%, radiochemical purity of >98%, molar activity of 20 ± 2 
GBq/µmol, and end of synthesis time of 125 ± 2 min (n = 4). Compound [18F]29 showed 
a significantly higher uptake in a PAR2-expressing prostate cancer cell line compared to 
the controls (P < 0.001, Figure 3.4) and is the first ever developed PAR2-targeted in vivo 
imaging agent.  
Compound [18F]29 can serve as a chemical tool that could provide insight into areas of 
PAR2 expression in vivo and has potential clinical applications as a non-invasive imaging 
approach for patient diagnosis, stratification, and treatment monitoring of various PAR2-
related cancers and inflammatory diseases. 
3.3.2 Future Work 
Compound [18F]29 is currently being evaluated through ex vivo biodistribution studies in 
mice and in vivo imaging in a xenograft mouse model of prostate caner. 
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3.4 Experimental Procedures 
3.4.1 General Methods 
All reagents were purchased from Sigma-Aldrich, ChemImpex, or Thermo Fischer 
Scientific and used without further purification. Peptides were synthesized using standard 
Fmoc-solid phase peptide synthesis (SPPS), cleaved from resin using 95% TFA, 2.5% 
TIPS, and 2.5% H2O for 5 h (except 21 and 25: 20% TFA, 2.5% TIPS, 77.5% DCM for 
1.5 h), precipitated in ice cold tert-butyl methyl ether, lyophilized, purified by preparative 
RP-HPLC, and further lyophilized to obtain a dry powder. Purity was assessed by 
analytical RP-HPLC and characterized by HRMS (Table 3.5). The analytical RP-HPLC 
was performed on a system consisting of an analytical Agilent Zorbax SB-C8 column 
(4.6 x 150 mm, 5 µm), Waters 600 controller, Waters in-line degasser, and Waters 
Masslynx software (version 4.1). Two mobile phases were used; eluent A (0.1% TFA in 
acetonitrile) and eluent B (0.1% TFA in MilliQ water). The flow rate was set at 1.5 
mLmin-1 over 10 minutes with an additional 5-minute wash (95% solvent A in solvent 
B). A Waters 2998 Photodiode array detector (200-800 nm) and an ESI-MS (Waters 
Quattro Micro API mass spectrometer) were used to monitor the column eluate. The 
preparative RP-HPLC used the same system, eluents, and detection method as mentioned 
above for the analytical RP-HPLC, except that a preparative Agilent Zorbax SB-C8 
column (21.2 x 150 mm, 5 µm) at a flow rate of 20 mLmin-1 was used. The high-
resolution mass spectra for all peptides were determined in positive mode using an 
electrospray ionization (ESI) ion source on a Bruker micrOToF II mass spectrometer. For 
small molecules, high-resolution mass spectra were determined in positive mode using an 
electron ionization (EI) ion source on a Thermo Scientific Double Focusing Sector mass 
spectrometer. Simulations Plus MedChem Designer ADMET Predictor was used to 
determine the cLogD values at a pH of 7.4.46 NMR spectra for appropriate compounds 
were recorded on a Bruker Avance III HD 400 spectrometer at 400 and 100 MHz for 1H 
and 13C experiments, respectively. All descriptive statistics are reported as mean ± SEM 
where applicable.  
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Table 3.5: HRMS data and purity of peptides 2, 6-7, 16-29, and 35. 
Cmpd # Molecular Formula (M) 
Evaluated 
HRMS m/z Calc. m/z Found m/z Purity 
2 C36H63N11O8 [M+H]+ 778.4939 778.4945 > 95 % 
6 C21H32N4O4 [M+Na]+ 427.2321 427.2309 > 95 % 
7 C30H49N9O6 [M+H]+ 632.3884 632.3892 > 95 % 
16 C23H35N5O5 [M+Na]+ 484.2536 484.2526 > 95 % 
17 C33H57N11O8 [M+H]+ 736.4470 736.4475 > 95 % 
18 C42H74N12O9 [M+H]+ 891.5780 891.5801 > 95 % 
19 C43H66FN11O9 [M+H]+ 900.5107 900.5129 > 95 % 
20 C49H77FN12O10 [M+H]+ 1013.5948 1013.5955 > 95 % 
21 C34H48FN5O5 [M+Na]+ 648.3537 648.3550 > 95 % 
22 C43H64FN11O8 [M+H]+ 882.5002 882.5011 > 95 % 
23 C49H75FN12O9 [M+H]+ 995.5842 995.5852 > 95 % 
24 C46H69FN12O9 [M+H]+ 953.5373 953.5398 > 95 % 
25 C43H65FN10O7 [M+H]+ 853.5100 853.5110 > 95 % 
26 C49H75FN12O9 [M+H]+ 995.5842 995.5855 > 95 % 
27 C49H75FN12O11 [M+H]+ 1027.5741 1027.5745 > 95 % 
28 C42H62FN11O8 [M+H]+ 868.4845 868.4864 > 95 % 
29 C40H58FN11O8 [M+H]+ 840.4532 840.4525 > 95 % 
35 C33H55N11O7 [M+H]+ 718.4364 718.4372 > 95 % 
Purity assessed by analytical RP-HPLC UV detection. 
 
3.4.2 Solid-Phase Peptide Synthesis 
All compounds (except 21 and 25) were synthesized on Rink amide MBHA resin (256 
mg, 0.1 mmol, 0.39 mmol/g) using standard Fmoc-SPPS procedures and a Biotage® 
SyrowaveTM automated peptide synthesizer (0.4 mmol of HCTU, 0.4 mmol of Fmoc-
amino acids, 0.6 mmol of DIPEA, 1 h coupling). Manual coupling of 5-isoxazoyl (0.3 
mmol) was performed using HATU (0.3 mmol) and DIPEA (0.6 mmol) for 24 h twice. 
Compound 21 and 25 were synthesized on 1,6-diaminohexane trityl resin (256 mg, 0.1 
mmol, 0.39 mmol/g).  
3.4.3 Solid-Phase Orthogonal Alloc Deprotection 
On resin peptide sequences were synthesized as described above but with Fmoc-
Lys(Alloc)-OH, Fmoc-Orn(Alloc)-OH, or Fmoc-Dpr(Alloc)-OH. After the sequence was 
synthesized on resin, the Alloc protecting group was selectively removed. Briefly, the 
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resin was swelled in DCM (15 min) and washed three times with dry DCM (3X 5 mL). 
The resin was placed under an inert N2 atmosphere and phenylsilane (296 µL, 2.4 mmol) 
in dry DCM (2 mL) was added to the resin. Tetrakis(triphenylphosphine) palladium(0) 
(23.1 mg, 20 µmol) was dissolved in dry DCM (1 mL) and added to the resin. The 
peptide column was flushed with N2 (2 min) before being shaken (5 min). The resin was 
washed three times with dry DCM (3X 5 mL). The procedure was repeated and shaken 
(30 min). The resin was washed four times with DCM (4X 5 mL) and DMF (4X 5 mL). 
3.4.4 Solid-Phase Conjugation of 4-Fluorobenzoic Acid (19-20, 22-
24, and 26-29) 
4-Fluorobenzoic acid (28.0 mg, 0.2 mmol), HCTU (82.7 mg, 0.2 mmol), and DIPEA (70 
µL, 0.4 mmol) were combined in DMF and shaken (5 min) to activate the acid. This 
mixture was then added to the peptide on resin (0.1 mmol) and shaken (2 h). The final on 
resin peptides (19-20, 22-24, and 26-29) were cleaved and purified as usual. 
3.4.5 Solution-Phase Conjugation of 4-Fluorobenzyl Chloride (21) 
Isox-Cha-Chg-NH(CH2)6NH2 was cleaved off resin and purified by RP-HPLC. The 
purified product containing a free primary amine (4.0 mg, 6.5 µmol) was dissolved in 
DMF (1 mL) followed by the addition of DIPEA (7.9 µL, 45.5 µmol). 4-Fluorobenzyl 
chloride (4.67 µL, 39 µmol) was added to the mixture and shaken (1 h). Following the 
addition of water, the product was lyophilized and purified by RP-HPLC.   
3.4.6 Solution-Phase Conjugation of 4-Fluorobenoic Acid (25) 
Isox-Cha-Chg-AR-NH(CH2)6NH2 (8) was cleaved off resin and purified by RP-HPLC. 
Peptide 8 containing a free primary amine (10.8 mg, 11.3 µmol) was dissolved in DMF 
(1 mL). Separately, 4-fluorobenzoic acid (7.9 mg, 56.3 µmol) and EDC hydrochloride 
(10.8 mg, 56.3 µmol) were dissolved in DMF (1 mL) and shaken (15 min). The EDC 
mixture was added to the peptide solution, stirred, and heated (60 °C, 2 h). Following the 
addition of water, the product was lyophilized and purified by RP-HPLC.   
60 
 
60 
3.4.7 SPPS Reaction Monitoring 
Two methods were used to monitor SPPS reactions. The first and more frequent method 
is the Kaiser Test. In this method, several resin beads were placed in a test tube followed 
by the addition of 42.5 mM phenol in ethanol (50 µL), 20 µM potassium cyanide in 
pyridine (50 µL), and 280.7 mM ninhydrin in ethanol (50 µL). The mixture was then 
heated (100 °C, 5 min). A positive test indicates the presence of a free amine, which is 
observed by the resin beads turning blue. A negative test indicates no free amine is 
present, which is observed by resin beads remaining the same colour. The second method 
is a small-scale resin cleavage. In this method, several beads and cleavage cocktail (500 
µL) are shaken, worked up, and the desired peptide is confirmed through HPLC-MS. 
3.4.8 Cell Lines and Culture Conditions 
All cell culture supplies were purchased from Thermo Fischer Scientific (Waltham, MA, 
US) unless otherwise stated. Human embryonic kidney (HEK-293T, ATCC, Manassas, 
VA, US), CRISPR/Cas9 PAR2 knockout HEK-293T (validated in Mihara et al., 2016), 
prostate cancer (PC3, ATCC, Manassas, VA, US), and CRIPSR/Cas9 PAR2 knockout 
PC3 cells (see Appendix 5 for validation) were cultured in Dulbecco’s Modified Eagle’s 
Medium (HEK293T-derived cell lines) and Ham’s F-12K Nutrient Mixture (PC3-derived 
cell lines) each supplemented with 10% fetal bovine serum (FBS), sodium pyruvate 
(1mM), and 100 penicillin streptomycin (100 units/mL).47 All culture performed under 
standard conditions (37 °C; 5% CO2). Trypsin (25mM) or PBS-EDTA (1mM) was used 
to passage cell lines. 
3.4.9 BRET β-Arrestin 2 Recruitment Assay 
HEK293T cells were transfected with BRET pair PAR2-eYFP (2 µg) and β-arrestin-2-
rluc (0.2 µg; generous gift from Michel Bouvier) using calcium phosphate and re-plated 
at 24 hours in tissue culture treated white 96-well plates (density approximately 8x102-
1x103 cells/µL). Serial dilutions of agonist (ranging from 300 µM to 300 pM depending 
on the agonist) were prepared in separate 96-well plates in Hank’s Balanced Salt Solution 
(HBSS). Cell media was removed from 96-well plate containing seeded cells. Agonist 
was added from negative control (HBSS) through to highest concentration using a 
61 
 
61 
multichannel pipette to seeded plates and incubated (37 °C, 10 min). Renilla luciferase 
substrate (h-coelenterazine) was added to each well (5 µM final) and incubated (37 °C, 
10 min). BRET ratios are recorded on Berthold Mithras LB 940. Responses are expressed 
as net emission of eYFP/rluc (calculated by subtracting HBSS baseline eYFP/rluc ratio 
from agonist eYFP/rluc ratio) and normalized to a positive control (1 at 300 µM). 
Experiments were completed in n ≥ 3 and fitted with a non-linear regression analysis 
four-parameter dose-response curve using GraphPad Prism 6 to determine EC50 values. 
3.4.10 Intracellular Calcium Release Assay 
HEK293T cells endogenously expressing PAR2 or CRISPR/Cas9 HEK293T PAR2 KO 
cells were lifted from confluent T75 flasks using PBS-EDTA (1 mM, 5 mL). PBS-EDTA 
was removed by centrifugation. Cells were re-suspended in 500 µL of Fluo-4 NW (no 
wash) dye solution and assay buffer (1 x HBSS, 20 mM HEPES) and incubated at 
ambient temperature on a rocking platform (30 min). Fluo-4 NW cell suspensions were 
then increased to the volume required for the assay with HBSS (with Ca2+ and Mg2+). 
Cells were aliquoted into cuvettes (2 mL/cuvette final volume) containing a magnetic 
stir-bar to keep cells in suspension for the assay. Individual cuvettes were loaded into a 
Photon Technologies Institute (PTI) spectrophotometer. Time-based assay parameters 
were assigned through PTI software as follows: excitation 480 nm, emission 530 nm with 
8 nm capture window, and 5000 seconds duration. Before the addition of agonist, 
individual cuvette emission was collected for approximately 10 seconds to obtain 
baseline emission. Agonist was pipetted into the cuvette (final concentration of 10 µM for 
2, 6, 7, and 16-29 and 100 µM for 1 and 13) and the fluorescence was measured. As a 
positive control, untreated cuvettes were treated with a calcium ionophore (ionomycin 
calcium salt in DMSO, 3 µM final) to obtain maximum possible calcium response. As a 
negative control, untreated cuvettes were treated with HBSS (no agonist). Response 
elicited by agonist treatment at individual concentrations (n ≥ 2) was expressed as a net 
percentage of the average maximum response (calculated by subtracting no agonist 
treatment percentage from agonist treatment percentage).  
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3.4.11 Synthesis of 4-(tert-butoxycarbonyl)-N,N,N-
trimethylbenzenammonium triflate (32) 
Synthesis was completed as previously described.48 Briefly, 4-dimethylaminobenzoic 
acid (1.00 g, 6.05 mmol) was dissolved in THF (50 mL) and cooled (0 °C), followed by 
the dropwise addition of trifluoroacetic anhydride (1.85 mL, 13.3 mmol) and stirring (35 
min). tert-Butanol (11.4 mL, 119 mmol) was then added and stirred at room temperature 
(120 min). A saturated solution of sodium bicarbonate (200 mL) was added to the 
reaction mixture and extracted with DCM (3X 100 mL, 3X 50mL). The organic layers 
were then combined, dried over MgSO4, and gravity filtered. The solvent was removed in 
vacuo, dissolved in DCM, and eluted through a silica pad with DCM (60 mL). Solvent 
was removed in vacuo, dissolved in dry DCM (30 mL), and cooled to 0 °C under N2. 
Methyl trifluoromethanesulfonate (0.86 mL, 7.61 mmol) was added to the mixture and 
stirred (60 min, 0 °C). Ice-cold diethyl ether (200 mL) was added to precipitate the 
product. The solid was then collected by vacuum filtration to yield white crystals (721 
mg, 31%). 1H-NMR (400 MHz, CD3COCD3); δ 8.22 (m, 4H), 3.93 (s, 9H), 1.60 (s, 9H) 
ppm; 13C-NMR (100 MHz, CD3COCD3); δ 205.19, 164.41, 134.70, 131.96, 121.72, 
82.66, 57.81, 28.16 ppm; HRMS (EI-MS): [M-H]+ 235.1567 (calc.) 235.1198 (found). 
3.4.12 Synthesis of N-succinimidyl 4-fluorobenzoate (34) 
4-Fluorobenzoic acid (140.1 mg, 1.0 mmol) was dissolved in DCM (10 mL). EDC 
hydrochloride (210.9 mg, 1.1 mmol) and NHS (126.6 mg, 1.1 mmol) were added and the 
solution was stirred (24 h). The organic solution was washed and extracted with water 
thrice (3X 10 mL), saturated sodium bicarbonate (10 mL), and saturated sodium chloride 
(10 mL). The organic layer was then dried with MgSO4, gravity filtered, and solvent 
removed in vacuo to obtain a white solid (121 mg, 52%). 1H-NMR (400 MHz, CDCl3); δ 
8.17 (m, 2H), 7.20 (m, 2H), 2.91 (s, 4H) ppm; 13C-NMR (100 MHz, CDCl3); δ 169.29 
(s), 166.02 (d, 1JCF = 256.2 Hz), 161.06 (s), 133.54 (d, 3JCF = 9.7 Hz), 121.54 (d, 4JCF = 
3.1 Hz), 116.46 (d, 2JCF = 22.1 Hz), 25.81 (s) ppm; HRMS (EI-MS): [M+] 237.0437 
(calc.) 237.0436 (found). 
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3.4.13 General Methods for Radiochemistry 
[18F]Fluoride was produced by a GE PETtrace 880 cyclotron (Lawson Cyclotron & PET 
Radiochemistry Facility, Lawson Health Research Institute, London, Ontario, Canada) 
through the 18O(p,n)18F reaction involving proton bombardment of [18O]H2O. GE Tracer 
Lab FXN was used for the automated synthesis and purification of [18F]SFB. Compounds 
were analyzed on a system consisting of an analytical RP-HPLC Waters Atlantis T3 
column (6 x 150 mm, 5 µm), Waters 1525 binary pump system, Waters in-line degasser, 
and Breeze software (version 3.30, 2002 Waters Corporation). Two mobile phases were 
used; eluent A (0.1% TFA in acetonitrile) and eluent B (0.1% TFA in MilliQ water). The 
flow rate was set at 1.5 mLmin-1 over 10 min with an additional 5-minute wash (95% 
solvent A in solvent B). A Waters 2487 Dual λ absorbance detector set at 220 nm and 
254 nm and a radioactive flow count detector were used to monitor the column eluate. 
Compounds were purified using semi-preparative RP-HPLC with the same system, 
eluents, and detection method as mentioned above for the analytical RP-HPLC, except 
that a semi-preparative Agilent Zorbax SB-C8 column (9.4 x 150 mm, 5 µm) at a flow 
rate of 4 mLmin-1 over 15 minutes with an additional 5-minute wash was used. A Biotage 
V-10 evaporator (Uppsala Sweden) was used to remove solvent. 
3.4.14 Synthesis of N-succinimidyl 4-[18F]fluorobenzoate ([18F]34) 
Synthesis was prepared on the GE Tracer Lab FXN using an automated synthesis 
procedure (see  Appendix 7 for the automated synthesis display). Aqueous [18F]F- was 
trapped on a Waters Sep-Pak Accell plus carbonated QMA light cartridge. The trapped 
[18F]F- was eluted into a reaction vial with a solution of acetonitrile/water (v/v 9:1, 1 mL) 
containing potassium carbonate (1.0 mg, 7.2 µmol) and Kryptofix 2.2.2 (7 mg, 18.6 
µmol). This solvent was removed azeotropically under vacuo with helium flow (75 °C). 
Anhydrous acetonitrile (2X 1 mL) was used to dry the [18F]F- twice under vacuo with 
helium flow (75 °C). 4-(tert-Butoxycarbonyl)-N,N,N-trimethylbenzenammonium triflate 
(5 mg, 13.0 µmol) in anhydrous DMSO (0.5 mL) was then added under helium flow. The 
reaction vial was sealed and stirred (120 °C, 8 min). The reaction was cooled (40 °C), 
followed by the addition of aqueous HCl (1 mL, 5 N) and further stirring (100 °C, 3 min). 
The reaction was cooled again (40 °C) followed by the addition of H2O (2.5 mL) to dilute 
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the reaction mixture. The product was trapped on a Waters Sep-Pak C18 light cartridge 
and eluted into a reaction vial containing NHS (N-hydroxysuccinimide, 20.0 mg, 0.17 
mmol) and EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) hydrochloride (200.0 
mg, 1.04 mmol) with acetonitrile (1.5 mL). The reaction mixture was stirred at room 
temperature (15 min). H2O (3.0 mL) was added to the reaction mixture followed by 
purification on semi-preparative RP-HPLC (36% MeCN in H2O, tR = 7-9 min) to yield 
[18F]34 (RCY = 31 ± 3% and RCP >98%, n = 4).  
3.4.15 Synthesis of Isox-Cha-Chg-AR-Dpr([18F]4FB)-NH2 ([18F]29) 
Compound 35 (1.0 mg, 1 µmol) was dissolved in acetonitrile (300 µL) followed by the 
addition of DIPEA (5 µL, 29 µmol). This mixture was added to a vial containing [18F]34 
and heated at 85 °C (15 min). The solution was cooled to room temperature, followed by 
the addition of water (0.7 mL) and purification on RP-HPLC (30-55% solvent A in 
solvent B, tR = 9-10 min) to yield [18F]29 (RCY = 37 ± 3%, RCP >98%, and Am = 20 ± 2 
GBq/µmol, n = 4). 
3.4.16 Determination of [18F]29 Molar Activity 
A calibration curve was made from five concentrations (1, 5, 10, 50, and 100 µM) of 29 
to determine the molar activity of [18F]29. For each of the five concentrations, at least 
two analytical HPLC runs were completed in order to obtain the area under the peak (at 
230 nm absorbance) associated with 29 within 5% of each other. This was plotted as 
concentration versus area under the peak and non-linear regression was performed to 
determine an equation of the line (Appendix 9). The molar activity was calculated based 
on determining the amount of radioactivity from the [18F]29 sample, the volume the 
[18F]29 sample was dissolved in, the area under the peak of the [18F]29 sample analytical 
HPLC trace at 230 nm, and the linear equation from the calibration curve. 
3.4.17 Cell uptake of [18F]29 
Cells were seeded into 6-well tissue culture plates at a density of 5.0 x 105 cells for PC3 
cells and 1.0 x 106 cells for PC3 PAR2 KO cells per 35-mm well. Appropriate seeding 
densities were determined prior to experiment. Cells were allowed to seed for 48 hours 
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before cell uptake was performed. On the day of experiment after [18F]29 was 
synthesized, serum media was removed and washed with HBSS (1 mL/well). A 2% BSA 
in HBSS solution (3 mL) was added to each well and incubated (37 °C, 30 min) to help 
block non-specific binding. The BSA solution was removed and 1mL of 50 to 100 kBq of 
[18F]29 in HBSS (with or without 20 µM of block peptide, 7) was added to each well and 
incubated (20 or 60 min). At the end of the incubation, plates were wash with HBSS (3X 
1mL/well) thrice to remove any unbound probe. This wash solution was collected and 
activity was measured on a gamma counter. PBS (1mL) was added to each well and cells 
were removed from the wells using a cell scrapper. Wells were then rinsed with PBS two 
additional times (2X 1 mL) to ensure all cells were collected. Collected cells were 
measured on a gamma counter to determine cell uptake activity. Experiments were 
completed in n ≥ 6. Data was decay corrected and expressed as a percentage of cell 
uptake over total activity (where total activity = wash + uptake). A two way ANOVA 
(cell condition, time) for percent uptake followed by a post-hoc Tukey multiple 
comparisons test was used to assess significance through GraphPad Prism 6 (significance 
set at 0.05).  
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Chapter 4  
4 Conclusions and Future Work 
4.1 Conclusions 
Aberrant function and over-expression of PAR2 is known to be involved in many 
cancers, including cancer progression, as well as multiple inflammatory diseases.1–17 
PAR2 is therefore an important biological target for the development of targeted 
therapeutics and imaging agents. Ligands targeting this receptor have been widely 
studied, with the development of various agonists and antagonists showing therapeutic 
potential. Some examples include agonists such as 2f-LIGRLO-NH2, Isox-Cha-Chg-AR-
NH2, and GB110 (Figure 4.1A) and antagonists such as GB88, C391, and K-14585 
(Figure 4.1B).18–22 Yet, imaging probes for this receptor are scarce. There are only a few 
fluorescent and tritiated probes that have been developed (examples shown in Figure 
4.1C), which all have a limited depth of penetration, lack of applicable in vivo imaging 
potential, and still show potential for significant PAR2 binding affinity improvement.23–25 
This thesis addresses this paucity of research though the design, synthesis, and evaluation 
of novel PAR2-targeting fluorescent and 18F-PET imaging agents.  
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Figure 4.1: Several reported leading (A) agonists, (B) antagonists, and (C) imaging 
probes targeting PAR2.18–22,24 
This thesis has three main goals. The first goal was the development and evaluation of 
novel PAR2-targeting peptides with primary amines to allow for facile conjugation of 
imaging components. The second goal was to develop an improved PAR2-selective 
fluorescent probe for use in various in vitro experiments and potential clinical 
applications in PAR2-related diseases. The third goal was the development of the first 
ever in vivo imaging agent targeting PAR2 for use in PET imaging, providing insight into 
PAR2 expression in vivo and potential clinical applications in the treatment and diagnosis 
of PAR2-related diseases. 
To achieve these goals, peptides were synthesized through standard Fmoc-SPPS, purified 
and characterized through RP-HPLC and HRMS, and evaluated for PAR2-binding 
through β-arrestin recruitment, calcium release, flow cytometry, and cell uptake assays. 
The beginning portion of Chapter 2 addressed the first goal of the thesis. Modifications 
were made to known PAR2-targeting peptides to include a free primary amine allowing 
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for facile conjugation of the various imaging components. Several synthesized peptides 
(8-11) showed strong potencies (EC50 = 10 nM to 23 nM, Table 2.1, Chapter 2) and 
selectivity for PAR2 with varying structural and hydrophobic properties. This 
preliminary work demonstrated the suitability of Isox-Cha-Chg-Ala-Arg related peptides 
for conjugation to various imaging components. 
The later portion of Chapter 2 addressed the second goal of the thesis. A Sulfo-Cy5 dye 
was conjugated to 11 to yield 15 (Isox-Cha-Chg-ARK(Sulfo-Cy5)-NH2). Peptide 15 
(Figure 4.2A) was found to be a PAR2-selective fluorescent probe with a greater than 
ten-fold increase in potency and binding affinity (EC50 = 16 nM and KD = 38 nM, 
respectively) compared to an analogue of the best known PAR2-targeting fluorescent 
probe (2f-LIGRLO(Cy5)-NH2, Table 2.3, Chapter 2). Peptide 15 was then further 
evaluated in an in vitro confocal microscopy experiment, showing PAR2-selective uptake 
in PC3 cells (Figure 2.4, Chapter 2). 
Chapter 3 addressed the third goal of the thesis. To achieve PAR2-targeing 18F-PET 
imaging agents, [19F]4-fluorobenzoyl-standards were conjugated to peptides for in vitro 
evaluation before generating the 18F-labeled analogue. A PAR2-targeting peptide of Class 
I showed promise (19, Table 3.1, Chapter 3), but many Class II peptides showed greater 
promise. First generation Class II peptides showed poor potency and loss of PAR2-
selectivity (21, Table 3.2, Chapter 3), but the second generation of Class II peptides 
showed substantial improvements in PAR2 potency comparable to 8-11 (22-25, Table 
3.3, Chapter 3). Unfortunately, the most potent candidates 22-24, were found to lose 
PAR2-selectivity (Table 3.3, Chapter 3). Thus, third generation Class II peptides were 
synthesized, many of which (26, 27, and 29) showed high potency and selectivity for 
PAR2 (Table 3.4, Chapter 3). The lead candidate, 29 (Isox-Cha-Chg-AR-Dpr(4-FB)-
NH2, EC50 = 13 nM) was synthesized successfully with fluorine-18 in place of fluorine-
19 using [18F]SFB to yield [18F]29 (Figure 4.2B) with a radiochemical yield of 37 ± 3%, 
greater than 98% radiochemical purity, molar activity of 20 ± 2 GBq/µmol, and end-of-
synthesis time of 125 ± 2 min (n = 4). Peptide [18F]29 was then evaluated in in vitro cell 
uptake studies using PC3 and PAR2 KO PC3 cells where it showed significant uptake in 
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the PAR2-expressing cells compared to controls (P < 0.001, Figure 3.4, Chapter 3). 
Peptide [18F]29 is the first PAR2-selective in vivo imaging agent ever developed. 
 
Figure 4.2: Structures of the lead PAR2-targeting (A) fluorescent probe, 15, and (B) PET 
imaging agent,  [18F]29, developed in this thesis.  
These novel probes, specifically 15 and [18F]29, are chemical tools that could provide 
insight into areas of PAR2 expression in vitro and in vivo with potential clinical 
applications in the diagnosis and treatment of various cancers and inflammatory diseases. 
 
4.2 Future Work and Outlook 
Studies to evaluate [18F]29 in normal mice are underway to determine ex vivo 
biodistribution of the tracer as well as to determine non-specific and specific uptake in 
various tissues through the use of a blocking peptide. In addition, a PC3 xenograft mouse 
model in immunodeficient mice will be used as a preclinical model of cancer for 
evaluation of [18F]29 uptake in the tumour and other tissue through PET imaging.  
In the long term, both probes (15 and [18F]29) will be evaluated in various in vitro and in 
vivo models of PAR2-related diseases, providing insights into PAR2 expression as well 
as advancing their potential for future clinical translation. More specifically in research 
purposes, 15 could be used in experiments such as PAR2-targeted competitive binding 
assays, determination of PAR2 expression levels for different cell types, and 
determination of PAR2 trafficking. Compound [18F]29 could potentially be used in 
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experimental research such as providing insight into endogenous PAR2 expression in 
vivo, providing insight into PAR2 expression and relevance in models of disease in vivo 
(e.g. a colon cancer model), and determining the effectiveness of new PAR2-targeting 
therapies in vivo. The research-based applications of 15 and [18F]29 will help the future 
development of PAR2-targeting imaging agents, ligands, and drug therapies, as well as 
improve the understanding of PAR2 expression and pathogenesis in relevant diseases.  
Clinically, since PAR2 is implicated in various cancers and inflammatory diseases and 
since its expression levels are linked to cancer staging, 15 has potential applications in 
pathological histology staining and intraoperative imaging for image-guided surgeries.1-17 
Similarly, [18F]29 has potential clinical applications as a non-invasive imaging approach 
for patient diagnosis, stratification, treatment monitoring, and early-stage detection of 
PAR2-related diseases. Both 15 and [18F]29 especially have strong potential in the 
stratification and treatment monitoring of patients with PAR2-related diseases as 
medicine continues to advance towards personalized medicine approaches. 
This thesis also provides a good platform for the development of targeted drug delivery 
conjugates for PAR2-related diseases. The targeted drug delivery approach generally 
involves a therapeutic component (e.g. a chemotherapy drug), a linker, and a targeting 
moiety, similar to the design of the imaging agents described in this thesis.26,27 The target 
is a biomarker which is inappropriately found in a disease in comparison to normal tissue, 
and so the targeted drug delivery approach helps maximize therapeutic effect while 
minimizing off-target side effects.26,27 The first component to this thesis that helps give a 
good platform for the development of targeted drug delivery conjugates is the extensive 
PAR2-ligand SAR. The second is the many lead candidates that could be used as the 
targeting moiety of the targeted drug delivery conjugate. The third is the amine handle on 
the various peptides, which would allow for facile conjugation of the PAR2-targeting 
moiety with the remaining component of the targeted drug delivery conjugate. 
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Appendices  
Appendix 1: Representative Examples of PAR2-Selectivity Measurements as 
Determined Through Calcium Response Assay in HEK293T and PAR2 KO 
HEK293T Cells 
 
(A) HEK293T cells + 100 µM of 13, (B) HEK293T PAR2 KO cells + 100 µM of 13, (C) 
HEK293T cells + 10 µM of 2, (D) HEK293T PAR2 KO cells + 10 µM of 2, (E) 
HEK293T cells + 10 µM of 12, (F) HEK293T PAR2 KO cells + 10 µM of 12. 
 
0 10 20 30 40 50 60 70 80 90 100
0
20
40
60
80
100
Time (s)N
et
 p
er
ce
nt
 o
f i
on
om
yc
in
 re
sp
on
se
 (%
)
13 (100 µM) 
0 10 20 30 40 50 60 70 80 90 100
0
20
40
60
80
100
Time (s)N
et
 p
er
ce
nt
 o
f i
on
om
yc
in
 re
sp
on
se
 (%
)
13 (100 µM) 
0 10 20 30 40 50 60 70 80 90 100
0
20
40
60
80
100
Time (s)N
et
 p
er
ce
nt
 o
f i
on
om
yc
in
 re
sp
on
se
 (%
)
2 (10 µM) 
0 10 20 30 40 50 60 70 80 90 100
0
20
40
60
80
100
Time (s)N
et
 p
er
ce
nt
 o
f i
on
om
yc
in
 re
sp
on
se
 (%
)
2 (10 µM) 
0 10 20 30 40 50 60 70 80 90 100
0
20
40
60
80
100
Time (s)N
et
 p
er
ce
nt
 o
f i
on
om
yc
in
 re
sp
on
se
 (%
)
12 (10 µM) 
0 10 20 30 40 50 60 70 80 90 100
0
20
40
60
80
100
Time (s)N
et
 p
er
ce
nt
 o
f i
on
om
yc
in
 re
sp
on
se
 (%
)
12 (10 µM) 
HEK293T cells HEK293T PAR2 KO cells  (A)                                                                                (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(C)                                                                                 (D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
(E)                                                                                  (F) 
77 
 
77 
Appendix 2: Validation of Specific Binding for Flow Cytometry Experiments 
#  Concentration (nM) 
Normalized fluorescence 
signal ± SEM 
Normalized fluorescence 
signal with block ± SEM* 
14  200 22.2 ± 2.3 10.8 ± 1.1 
14  1000 64.5 ± 2.1 38.2 ± 0.2 
15  200 24.8 ± 4.2 7.3 ± 2.3 
15  1000 60.2 ± 7.2 32.7 ± 7.4 
*Block done with 20 µM of a known PAR2-selective peptide, Isox-Cha-Chg-AR-NH2 
(7). 
Appendix 3: Characterization of Synthesized Peptides (2, 6-12, and 14-15) 
All peptides were >95% pure as determined by analytical RP-HPLC UV detection (see 
chromatograms below).  
2f-LIGRLO-NH2, 2 (C36H63N11O8):  
 
tR = 9.36 min; HRMS (ESI-MS): [M+H]+ 778.4939 (calc.) 778.4945 (found). 
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Isox-Cha-Chg-NH2, 6 (C21H32N4O4): 
 
tR = 9.85 min; HRMS (ESI-MS): [M+Na]+ 427.2321 (calc.) 427.2309 (found). 
 
 
Isox-Cha-Chg-AR-NH2, 7 (C30H49N9O6): 
 
tR = 9.57 min; HRMS (ESI-MS): [M+H]+ 632.3884 (calc.) 632.3892 (found). 
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Isox-Cha-Chg-AR-NH(CH2)6NH2, 8 (C36H62N10O6): 
 
tR = 9.29 min; HRMS (ESI-MS): [M+H]+ 731.4932 (calc.) 731.4944 (found). 
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Isox-Cha-Chg-ARLK-NH2, 9 (C42H72N12O8): 
 
tR = 9.09 min; HRMS (ESI-MS): [M+H]+ 873.5674 (calc.) 873.5685 (found). 
 
 
Isox-Cha-Chg-ARAK-NH2, 10 (C39H66N12O8): 
 
tR = 9.38 min; HRMS (ESI-MS): [M+H]+ 831.5205 (calc.) 831.5197 (found). 
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Isox-Cha-Chg-ARK-NH2, 11 (C36H61N11O7): 
 
tR = 9.14 min; HRMS (ESI-MS): [M+H]+ 760.4834 (calc.) 760.4841 (found). 
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Isox-Cha-Chg-ARK(COCH3)-NH2, 12 (C38H63N11O8): 
 
tR = 9.15 min; HRMS (ESI-MS): [M+H]+ 802.4939 (calc.) 802.4952 (found). 
 
 
2f-LIGRLIO(Sulfo-Cy5)-NH2, 14 (C68H98N13O15S2-): 
 
tR = 8.92 min; HRMS (ESI-MS): [M-] 1400.6747  (calc.) 1400.6714 (found). 
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Isox-Cha-Chg-ARK(Sulfo-Cy5)-NH2, 15 (C68H96N13O14S2-): 
 
tR = 8.87 min; HRMS (ESI-MS): [M-] 1382.6641 (calc.) 1382.6589 (found). 
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Appendix 4: PAR2 β-Arrestin 2 Recruitment Dose-Response Curves for Peptides 1, 
2, 6-12, and 14-15 in HEK293T Cells 
Compound 1 
 
Compound 2 
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Compound 6 
 
Compound 7 
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Compound 8 
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Compound 10 
 
Compound 11 
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Compound 12 
 
Compound 14 
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Compound 15 
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Appendix 5: Representative Examples of PAR2-Selectivity Measurements as 
Determined Through Calcium Response Assay in PC3 and PAR2 KO PC3 Cells 
 
(A) PC3 cells + 100 µM of 13, (B) PC3 PAR2 KO cells + 100 µM of 13, (C) PC3 cells + 
100 µM of 2, (D) PC3 PAR2 KO cells + 100 µM of 2. 
 
PC3 cells PC3 PAR2 KO cells 
0 20 40 60 80 100
0
20
40
60
80
Time (s)N
et
 p
er
ce
nt
 o
f i
on
om
yc
in
 re
sp
on
se
 (%
)
2
(100 µM) 
0 20 40 60 80 100
0
20
40
60
80
Time (s)N
et
 p
er
ce
nt
 o
f i
on
om
yc
in
 re
sp
on
se
 (%
)
2
(100 µM) 
0 20 40 60 80 100
0
20
40
60
80
Time (s)N
et
 p
er
ce
nt
 o
f i
on
om
yc
in
 re
sp
on
se
 (%
)
13
(100 µM) 
0 20 40 60 80 100
0
20
40
60
80
Time (s)N
et
 p
er
ce
nt
 o
f i
on
om
yc
in
 re
sp
on
se
 (%
)
13
(100 µM) 
(A)                                                                                (B)
(C)                                                                                 (D)
91 
 
91 
Appendix 6: Representative Examples of PAR2-Selectivity Measurements as 
Determined Through Calcium Response Assay in HEK293T and PAR2 KO 
HEK293T Cells 
 
(A)                                                         (B)     
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(A) HEK293T cells + 100 µM of 13, (B) HEK293T PAR2 KO cells + 100 µM of 13, (C) 
HEK293T cells + 10 µM of 7, (D) HEK293T PAR2 KO cells + 10 µM of 7, (E) 
HEK293T cells + 10 µM of 23, (F) HEK293T PAR2 KO cells + 10 µM of 23, (G) 
HEK293T cells + 10 µM of 29, (H) HEK293T PAR2 KO cells + 10 µM of 29. 
Appendix 7: GE Tracer Lab FXN Automated Synthesis Display. 
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Appendix 8: Fluorine-18 Co-Injection Radio-traces and Chromatograms.  
 
(A) Overlay of RP-HPLC radio-trace and chromatogram of SFB and [18F]SFB co-
injection and of (B) 29 and [18F]29 co-injection. 
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Appendix 9: Calibration Curve of 29 to Determine Molar Activity of [18F]29. 
 
Appendix 10: Characterization of Synthesized Peptides (2, 6, 7, 16-29, and 35) 
All peptides were >95% pure as determined by analytical RP-HPLC UV detection (see 
chromatograms below).  
2f-LIGRLO-NH2, 2 (C36H63N11O8): 
 
tR = 9.36 min; HRMS (ESI-MS): [M+H]+ 778.4939 (calc.) 778.4945 (found). 
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Isox-Cha-Chg-NH2, 6 (C21H32N4O4): 
 
tR = 9.85 min; HRMS (ESI-MS): [M+Na]+ 427.2321 (calc.) 427.2309 (found). 
 
 
Isox-Cha-Chg-AR-NH2, 7 (C30H49N9O6): 
 
tR = 9.57 min; HRMS (ESI-MS): [M+H]+ 632.3884 (calc.) 632.3892 (found). 
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Isox-Cha-Chg-G-NH2, 16 (C23H35N5O5): 
 
tR = 8.91 min; HRMS (ESI-MS): [M+Na]+ 484.2536 (calc.) 484.2526 (found). 
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2f-LIGRAO-NH2, 17 (C33H57N11O8): 
 
tR = 9.19 min; HRMS (ESI-MS): [M+H]+ 736.4470 (calc.) 736.4475 (found). 
 
 
2f-LIGRLIO-NH2, 18 (C42H74N12O9): 
 
tR = 9.37 min; HRMS (ESI-MS): [M+H]+ 891.5780 (calc.) 891.5801 (found). 
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2f-LIGRLO(4-FB)-NH2, 19 (C43H66FN11O9): 
 
tR = 9.19 min; HRMS (ESI-MS): [M+H]+ 900.5107 (calc.) 900.5129 (found). 
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2f-LIGRLIO(4-FB)-NH2, 20 (C49H77FN12O10): 
 
tR = 9.04 min; HRMS (ESI-MS): [M+H]+ 1013.5948 (calc.) 1013.5955 (found). 
 
 
Isox-Cha-Chg-NH(CH2)6NH-4-FB, 21 (C34H48FN5O5): 
 
tR = 9.39 min; HRMS (ESI-MS): [M+Na]+ 648.3537 (calc.) 648.3550 (found). 
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Isox-Cha-Chg-ARK(4-FB)-NH2, 22 (C43H64FN11O8): 
 
tR = 9.58 min; HRMS (ESI-MS): [M+H]+ 882.5002 (calc.) 882.5011 (found). 
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Isox-Cha-Chg-ARLK(4-FB)-NH2, 23 (C49H75FN12O9): 
 
tR = 9.30 min; HRMS (ESI-MS): [M+H]+ 995.5842 (calc.) 995.5852 (found). 
 
 
Isox-Cha-Chg-ARAK(4-FB)-NH2, 24 (C46H69FN12O9): 
 
tR = 8.52 min; HRMS (ESI-MS): [M+H]+ 953.5373 (calc.) 953.5398 (found). 
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Isox-Cha-Chg-AR-NH(CH2)6NH-4-FB, 25 (C43H65FN10O7): 
 
tR = 8.96 min; HRMS (ESI-MS): [M+H]+ 853.5100 (calc.) 853.5110 (found). 
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Isox-Cha-Chg-ARK(Ahx-4-FB)-NH2, 26 (C49H75FN12O9): 
 
tR = 9.22 min; HRMS (ESI-MS): [M+H]+ 995.5842 (calc.) 995.5855 (found). 
 
 
Isox-Cha-Chg-ARK(AEEA-4-FB)-NH2, 27 (C49H75FN12O11): 
 
tR = 8.92 min; HRMS (ESI-MS): [M+H]+ 1027.5741 (calc.) 1027.5745 (found). 
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Isox-Cha-Chg-ARO(4-FB)-NH2, 28 (C42H62FN11O8): 
 
tR = 8.81 min; HRMS (ESI-MS): [M+H]+ 868.4845 (calc.) 868.4864 (found). 
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Isox-Cha-Chg-AR-Dpr(4-FB)-NH2, 29 (C40H58FN11O8): 
 
tR = 8.87 min; HRMS (ESI-MS): [M+H]+ 840.4532 (calc.) 840.4525 (found). 
 
 
Isox-Cha-Chg-AR-Dpr-NH2, 35 (C33H55N11O7): 
 
tR = 8.74 min; HRMS (ESI-MS): [M+H]+ 718.4364 (calc.) 718.4372 (found). 
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Appendix 11: PAR2 β-Arrestin 2 Recruitment Dose-Response Curves for Peptides 1, 
2, 6-7, and 16-29 in HEK293T Cells 
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Appendix 12: NMR of N-succinimidyl 4-fluorobenzoate (34) 
 
 
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
f1 (ppm)
-1000
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
11000
12000
JCL-1-63.1.ﬁd
H-1 using the Bruker 400
PROTON-UWO CDCl3 /home/nmr-data/Luyt/jlesarge/B400 Luyt 4
4
.1
6
2
.0
0
1
.9
5
1
.5
7
2
.9
1
7
.1
7
7
.1
9
7
.2
0
7
.2
2
7
.2
6
8
.1
5
8
.1
6
8
.1
7
8
.1
7
8
.1
9
1H NMR: 
O
O
N
O
O
F
O
O
N
O
O
F
13C NMR: 
30405060708090100110120130140150160170
f1 (ppm)
-10000
0
10000
20000
30000
40000
50000
60000
70000
80000
90000
100000
110000
120000
130000
140000
150000
160000
170000
180000
190000
200000
JCL-1-63.2.ﬁd
H-1 using the Bruker 400
CARBON-niteQ CDCl3 /home/nmr-data/Luyt/jlesarge/B400 Luyt 4
2
5
.8
1
7
6
.8
4
7
7
.1
6
7
7
.3
6
7
7
.4
8
1
1
6
.3
5
1
1
6
.5
7
1
2
1
.5
2
1
2
1
.5
6
1
3
3
.4
9
1
3
3
.5
9
1
6
1
.0
6
1
6
5
.7
4
1
6
8
.3
0
1
6
9
.2
9
117 
 
117 
Appendix 13: NMR of 4-(tert-butoxycarbonyl)-N,N,N-trimethylbenzenammonium 
triflate (32) 
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